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ABSTRACT
We have conceptualized a new class of polymer-linker-drug conjugates to achieve
targeted drug delivery for the systemic treatment of cancer and other inflammatory diseases. The
physiochemical properties of the polymer allow the conjugate to circulate longer in the body by
minimizing renal and hepatic clearance, thereby improving the pharmacokinetics of the attached
drugs. Traditionally, linkers are degraded by acidity or by some ubiquitous intracellular
enzymes. We incorporate linkers that are sensitive to a specific extracellular enzyme whose
overexpression is co-localized with the diseased tissue. The drug molecules remain inactive
when attached to the polymer, thus preventing normal tissues from harmful side effects. When
the conjugate is transported to the diseased area where there is a high level of the target enzyme,
the linkers are cleaved to release the drugs at the specific site.
As an example, we designed and synthesized two generations of novel polymer-peptide-
drug conjugates for the tumor-targeted delivery of chemotherapeutics. To allow for passive
targeting and enhanced permeation and retention (EPR), dextran with a size greater than 6 nm
was selected as the polymeric carrier. This biocompatible and biodegradable carrier was
chemically modified to allow for conjugation with doxorubicin and methotrexate, two common
chemotherapeutics with undesirable side effects. Since matrix-metalloproteinases (MMPs) are
associated with a number of types of cancer and their functions are essential to disease
progression, including degrading extracellular matrix, releasing angiogenic factors and activating
growth factors, we explored the possibility of MMP-mediated drug release. The synthesis
procedures combined solid phase and solution phase techniques to enable flexibility in the linker
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design and in the charge modification of the polymer. This scaleable and robust process
produced new conjugates that demonstrated excellent stability under physiological conditions
and optimized sensitivity to enzymatic cleavage by MMP-2 and MMP-9.
The new conjugate, dextran-peptide-methotrexate, was assessed for its in vivo anti-tumor
efficacy and systemic side effects. It was compared to free methotrexate and a similar conjugate,
differing by an MMP-insensitive linker, at equivalent intraperitoneal dosages administered
weekly. The MMP-sensitive conjugate resulted in effective inhibition of in vivo tumor growth in
each of the two separate tumor models that overexpress MMP-2 and MMP-9 (HT-1080 and U-
87). In contrast, free methotrexate resulted in no significant tumor reduction in the same models.
Neither free methotrexate nor the conjugate caused any tumor inhibition in mice bearing RT- 112,
a slower-growing model which expresses significantly less MMP than HT-1080 and U-87 . The
anti-proliferative effect of the drug contributed to the inhibition of tumor growth. Systemic side
effects caused by the MMP-sensitive conjugates were tolerable. MMP-insensitive conjugates,
though able to inhibit tumor growth, caused toxicity in the small intestine and bone marrow and
the experiment was terminated after one injection.
We conducted a biodistribution study in HT-1080 bearing mice to investigate the
targeting mechanism of the new conjugate. Independent of the linker sequence, passive targeting
was evidenced by the prolonged plasma circulation and higher tissue accumulations of the
conjugates in comparison with free methotrexate. The ratios of drug accumulation at the tumor
versus the major site of side effects (small intestine) for both conjugates were enhanced by the
EPR effects. The difference in the drug accumulation at the tumor site was insignificant between
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conjugates with MMP-sensitive and MMP-insensitive linkers. We concluded that the tumor
targeting effect of the dextran-peptide-methotrexate conjugate was dominantly due to passive
targeting and EPR. The difference in the systemic side effects observed for the conjugates with
different linkers was attributed to their varying susceptibility towards enzymes in normal tissues.
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CHAPTER I : BACKGROUND
Original concept and current status of polymer-drug conjugates
The concept of a polymer-drug conjugate was first proposed by Ringsdorf in the 1970s'
His idea of how this drug delivery system can enhance targeting of small molecular drug
molecules is illustrated in Figure I-1. With proper physiochemical characteristics, the polymer
backbone can improve drug properties, for example, by enhancing drug solubility, preventing
drug degradation and lowering excretory clearance. Drug molecules are attached to a polymer
backbone via biodegradable linkers. Homing signals are covalently joined to the polymer to help
localize the polymer-drug conjugates to the target site.
Targeting moiety
Polymer
Backbone
Biodegradable linker
Figure I-1. Illustration of the concept of a polymer-drug conjugate proposed by Ringsdorf'
Since the inception of this concept, the development of polymer-drug conjugates,
especially for anti-cancer targeting, has moved forwards with promising results. Notably, the
idea has been popularized by the work of Kopecek's lab using HPMA as the polymeric carrier.
PEG was first used to conjugate protein to increase solubility and stability, and to reduce
immunogenicity. Later, PEG was useful for attaching small molecular weight chemotherapeutics
for anti-cancer treatment. Listed in Table I-i are a number of polymer-drug conjugates that have
entered clinical trials. These conjugates all make use of the idea of passive targeting to achieve
tumor-targeted delivery and this concept will be discussed further in a later section. In one of
these conjugates, galatosamine is used as a homing signal to target to the liver tissue. Along the
same line, ligands for recognizing cancer cells have been evaluated by numerous groups and the
implementation of this idea will also be discussed. Last but not least, the linkage and its timely
cleavage are essential for a successful application and we will explore the common linkages that
have been developed in this field.
Table I-1. Polymer-drug conjugates in clinical trials as anticancer agents (adapted from source 2)
HPMA copolymer-doxorubicin CRC/Pharmacia Amide Phase II
HPMA copolymer-paclitaxel Pharmacia Ester Phase I
HPMA copolymer-platinate Access Pharmaceuticals Malonate Phase I
Polyglutamate-camptothecin Cell Therapeutics Ester Phase I
CRC, UK Cancer Research Campaign; HPMA, N-(2-hydroxypropyl)methylacrylamide; PEG, polyethylene glycol
I
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Pharmacokinetics and drug targeting
Drug targeting is achieved when the biodistribution of drug is altered to favor its
accumulation in the target tissue. This subject can be understood from the perspective of
pharmacokinetics. Pharmacokinetics is the study of drug and drug carrier dynamics inside the
body and includes the quantitative assessment of absorption, uptake, metabolism and elimination
processes. Most relevant to our discussion is the concept of clearance, which is fundamental to
pharmacokinetics. Figure I-2 presents a simple schematics showing inter-connected organs to
illustrate this concept.
CLi
v'tumor
Figure 1-2. Clearance concept in pharmacokinetics. Diagram is modified from the reference 3
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i
Clearance by a specific organ, CLi , is defined as
CL Qi(Ca - Cv)
Ci,a
where Qi is the plasma flow rate perfusing the organ. Ci,a and Ci,v are the drug carrier
concentrations in the influent and effluent blood plasma respectively. Let a be the amount of
drug molecules loaded per drug carrier, the rate of drug accumulation in a specific organ is given
by
dxi
= CLia Cpdt
which, after integration is given by
Xi = CLia Cp dt = CLi a AUCp
t=o
Here, Xi is the total amount of drugs in a specific organ. AUCp is called the "area under the
concentration-time curve" for plasma. A useful parameter is the drug targeting ratio (Ftarget). It
equals the fraction of the total dose delivered to the target site and can be calculated as:
F. CLtarget
target CL
total
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When the drug targeting ratio is plotted against the two clearance terms, it is clear that a
successful strategy involves maximizing CLtumor while minimizing CLtotal
(Figure 1-3). Physically, this means that the drug needs to be retained in the body for a long
enough time to allow the drug to reach the target. Once at the target site, drugs must be taken up
effectively by the target tissue.
Drug
targeting
ratio
09-
0.8-
07-
0,6-
0.5-
0.4-
0.3
0.2-
0.1
0 220
Uptake clearance at the
102
Total body
Figure 1-3. Drug targeting ratio as a function of total body clearance and target site uptake
clearance.
0V
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Passive targeting
The principle of passive targeting is to decrease total body clearance of the drug carrier
(CLtotal ). As seen from the equation that defines drug targeting ratio in the last section, a
prolonged circulation in the plasma results in a higher fraction of drug carriers distributed to the
tumor tissues. The strategies to minimize body clearance have been considered for two organs,
the liver and the kidney, because they are known to be the major elimination sites in the body.
Hashida and Takakura reviewed the current status of the macromolecular drug delivery systems3 ,
relating the physiological features of these two organs to the clearance of macromolecules. The
glomerular capillaries in the kidney are fenestrated, with the pores of radii estimated to be
20 -30 nm. The basement membrane acts as a size and charge barrier, which appears to hinder
the transport of molecules greater than 6 nm. In the liver, the basement membrane is absent and
the capillaries are characterized by having fenestrate of about 100 nm and endothelial gaps from
100 nm to 1000 nm. The passage of macromolecules is not restricted. However, cellular uptake
of the drug carriers can be lowered by decreasing the interaction between the cells and the
carriers . In general, cationic molecules tend to bind to the cell surface and strongly anionic
species facilitate receptor mediated endocytosis. Consistent with these features, macromolecules
with a size greater than approximately 6 nm (MW ~50,000) have exhibited a marked inhibition
on renal clearance. A slightly anionic carrier, for example, carboxymethyl dextran, appears to
elicit the least uptake by liver cells and its hepatic clearance is similar to that of the fluid phase
endocytosis (-10 gl/hr in mice).
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In addition to controlling the size and the charge of a drug carrier, Kilbanov and a
number of laboratories have demonstrated the benefit of a hydrophilic character using
poly(ethylene-glycol) (PEG) stealths in liposomes 4, polymeric micelles 5 and nanoparticles 6, 7
A layer of linear hydrophilic polymers surrounding the carrier in the core provides shielding
effect by preventing absorption onto cell surface in the eliminating organ. With the appropriate
molecular weight and density 8, 9, the PEG brush also inhibits proteins from interacting with the
core through steric hindrance. These features prolong the circulation of polymeric carriers in the
circulation, that is, CLtotal is decreased.
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Enhanced permeation and retention
In the targeted drug delivery for cancer treatment, the use of macromolecules as drug
carriers confers one additional advantage because of tumor physiology 0. Most capillaries in
normal tissues are continuous, with small pore radii of 6.7-8.0nm and large pore radii of 20-
28nm. They are found in the muscle, lung, skin, subcutaneous tissues, serous and mucous
membranes. Transport of macromolecules (above approx. 7nm) across these capillaries is
negligible. In contrast, tumor blood vessels are leaky and the basement membrane is absent. By
observing the transvascular transport of liposomes in an implanted dorsal skin chamber of a
tumor-bearing mouse, Jain's laboratory has determined the cutoff pore size of the tumor vessel to
be 400-600 nm l. This features is attributed to the expression of angiogenic factors and various
collagen degrading enzymes 12. Large drug carriers can selectively reach malignant tissues while
sparing most of the normal tissues. (Liver, bone marrow, spleen and kidney are the key
exceptions.)
Maeda and coworkers observed that macromolecules are preferentially retained in tumor
tissues. They conjugated the antitumor protein neocarzinostatin to a styrene and maleic acid
copolymer (SMANCS) and reported a poor recovery of the conjugates in the effluent blood and
lymph. This phenomenon was termed enhanced permeation and retention (EPR). The researchers
explained that EPR was due to the augmented leakiness of the tumor blood vessels and the lack
of a lymphatic drainage in the tumor tissue 13. While the macromolecules could readily
extravasate into the tumor tissue, their paths to return to the circulation were blocked.
26
Active Targeting
Active targeting is achieved by increasing the uptake clearance at the target site (CLrget).
Using tumor targeting to illustrate this concept, the common approach is attaching specific
ligands to the polymer that can bind to moieties expressed on tumor cells. Without these ligands,
the conjugate is presumably internalized by tumor cells via fluid-phase endocytosis, a slow and
non-specific cellular process. The targeting ligands enable the conjugate to be taken up via the
route of receptor-mediated endocytosis.
There are several factors to be considered when employing this strategy. First, since
tumor cells are derived from host cells, the surface antigens of tumor cells are never unique. The
difference between the host and the tumor cells is the level of expression. Thus the antigen
chosen should give enough selectivity between the tumor and the host tissues. Second, although
a tight binding between the ligand and the antigen is essential, a high binding affinity may hinder
even distribution'4. This problem is more severe with a large polymer-drug conjugate. Jain has
found that the pathophysiology of the solid tumor causes the build-up of a positive osmotic
pressure' 5. The barrier to the movement deep into the tumor core increases with the size of the
molecules". Third, the antigen must be internalized by the tumor cells in order to facilitate
receptor-mediated endocytosis. Antigen shedding has a negative impact on the effectiveness of
this tumor-targeting approach.
The only polymer-drug conjugate with a targeting ligand in current clinical trial makes
use of galactosamine (Table I-1)16. It is a molecule capable of binding to the asialoglycoprotein
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receptor. The conjugate is designed to treat liver cancer. However, asialoglycoprotein receptors
are not only expressed by hepatoma but also by normal hepatocytes.
Alternatively, a-fetoprotein is an example of a tumor-specific antigen. The antibody
against this protein was attached to a polyglutamate-daunomycin conjugate to enhance the
tumor-targeted delivery. The immunoconjugate was more effective than the polyglutamate-
daunomycin conjugate in an in vivo study'7 . Besides using antibody or antibody fragments'8 , the
attachment of a metabolite represents another interesting class. Notably, Low's group has done
extensive investigation in using folate as a targeting ligand. Folate is an essential vitamin for
biosynthesis. Because of the rapid proliferative rate of cancer cells, folate receptors are
overexpressed on their surfaces. Although HPMA-folate-fluorescein conjugates showed
improved cellular uptake in vitro, HPMA-folate-doxorubicin conjugates were unable to show
any significant targeting effect in vivo19. Other targeting ligands include transferrin, hormones,
growth factors, carbohydrates and lectins.
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Linkage Design
Review of linkers for intracellular release
After the polymer-drug conjugates reach the target tissues, a mechanism is needed to
release covalently attached drugs such that the active components can exert their
pharmacological properties. A frequently used approach relies on an intracellular drug release.
The polymer-drug conjugates are presumably internalized into the cell by endocytosis. The
intracellular trafficking process then proceeds to the endosomal and lysosomal pathways. The
presence of proteases and the acidity of these compartments allow the design of linkers to be
degraded intracellularly.
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Figure I-4. A polymer-drug conjugate with a GFLG tetrapeptide linker for the lysosomal release
of the attached drug20
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A widely published tetrapeptide linker GFLG was designed by the labs of Kopecek and
Duncan20 (Figure 1-4). The in vitro results showed that all the doxorubicin bound at the carboxyl
end of tetrapeptide could be released in about 30 hours after mixing with rat liver lysosomal
enzymes. The group found that cathepsin B was primarily responsible for the enzymatic
cleavage21 . The rate of cleavage depended on the composition of the peptide. In contrast to
GFLG, GG is the control peptide that remained uncleaved in the presence of lysosomal
enzymes2 2 . Harada compared glycine-containing oligopeptides of different lengths for their
susceptibility to be cleaved by lysosomal enzymes, showing that Gly-Gly-Gly was a linker that
was capable of liberating bound camptothecin from the carboxymethyl dextran carrier through
the action of cathepsin B. The study also indicated the dependence of enzymatic recognition on
the length of the glycine sequence 23
The pH drops from 7.5 to about 5-6 in endosomes and about 4-5 in lysosomes. This
suggests an acid- sensitive linker should provide an avenue for intracellular release. The two
types of linkage used in this category are the hydrazone and cis-aconityl linkers. They are both
relatively stable in physiological pH and are capable of liberating the bound drugs at low pH.
The mechanisms of drug release are shown in Figure 1-5 and Figure 1-6. The hydrazone linkage
has a half-life of about 1-2 days at pH 5-6 whereas less than 20% of the linkage was broken
over 30 days at pH 7.5 24, 25. Examples of polymer-drug conjugates containing the hydrazone
linkage are HPMA-doxorubicin, PEG-doxorubicin, PEG-paclitaxel, polyglutamate-streptomycin
and dextran-strptomycin26 . The cis-aconityl linkage has a half-life of 3 hours at pH 4.0 and 96
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hours at pH 7.5 27. Examples using this linkage include poly(aminopropyl)dextran-daunorobicin,
aliginate-daunomycin, chitosan- adriamycin and HPMA-doxorubicin26 .
0
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Acid-triggered drug release from a polymer-drug conjugate containing a hydrazone
DRUG
H
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Figure I-6. Acid-triggered drug release from a polymer-drug conjugate containing an cis-aconityl
linkage.
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Figure 1-5.
linkage
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Linkers in this group only target the drugs to be released inside cells, but do not
differentiate cells in the target tissue from normal tissues.
Review of linkers for extracellular release
In an approach called ADEPT (Antibody-Directed Enzyme Prodrug Therapy), drug
release from polymer-peptide-drug conjugates is mediated by a foreign enzyme, which is first
targeted to the tumor tissue by linking to a tumor-specific antibody 28 29. One limitation of this
approach is the immunogenicity of the antibody-enzyme conjugate. Likewise, it is also necessary
to ensure that the enzyme introduced is cleared from the blood stream prior to the injection of the
polymer-drug conjugate.
A similar approach as ADEPT is termed PDEPT (Polymer-Directed Enzyme Prodrug
Therapy) 30' 31. Injection of polymer -drug conjugates is followed by the administration of
polymer-enzyme conjugates. A polymer-enzyme conjugate consists of a "foreign" enzyme and
tends to localize to tumor tissue due to EPR. The linker in the polymer-drug conjugate is
designed for cleavage by the "foreign" enzyme. Again, the introduction of a foreign enzyme
faces the potential problems of immunogenicity.
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Proposal of linkers for disease-associated-enzyme-mediated release
In the design of a new polymer-drug conjugate, we explore the possibility of drug release
via the mediation of an intrinsic enzyme in the extracellular space. Our idea is motivated by the
fact that the microenvironment of a disease is shaped by the overexpression of extracellular
enzymes, that are either secreted or membrane bound. Especially, progression of an
inflammatory disease, such as cancer, arthritis and cardiovascular disease, is correlated with the
proteolytic events of specific enzymes. Most of these enzymes are proteases and have preferred
substrates. The substrate specificity of a particular enzyme can be deduced from the study of its
natural substrates or from the screening of synthetic substrates. A peptide linker mimicking the
enzyme substrate between the drug molecule and the polymeric carrier can theoretically provide
a useful drug release mechanism and improve the extent of active targeting. As an example, a
partial list of tumor-associated enzymes and their substrate specificities are shown in Table 1-2.
This information can potentially be applied for the design of a linker in a tumor-targeted drug
delivery system.
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Table 1-2. Partial list of tumor-associated protease and their substrate specificities
Protease Class Substrate specificity Comments References
Prostate specific Serine HSSKLQ4- Chymotrypsin-like substrate specificity.
antigen (PSA) (most selective) Uniquely expressed by prostate glandular cells. 32, 33
SS(Y/F)Y4-S(G/S) Elevated level in prostate carcinoma. Secreted
(most sensitive) by PC-82 human prostate tumor model
Human kallikrein 2 Serine (Q/E)(R/K/H)R-LXY Trypsin-like substrate specificity. Uniquely
(hk2) (cleavage sites in expressed by prostate glandular cells. Elevated 34
semenogelin I and II) level in prostate carcinoma. Activate PSA and
PFR- uPA. Cleave fibronectin
Urokinase-type Serine KKSPGRVVGGSVAAH Chymotrypsin family. Overexpressed in a
plasminogen (sequence of plasminogen) number of epithelial cancers. Involved in 36
activator (uPA) GPR, tumor-associated fibrolysis, associated with 37
malignancy. 38
GPK-k
Fibroblast Serine Collagenolytic activity- Cell surface antigen of reactive tumor stromal
activating protein ia sequence specificity not fibroblasts in epithelial cancers or granulation 39
(FAPa) determined tissue during wound healing. Degrade ECM.
Dipeptidyl peptidase- AP4. Normal tissues are FAP negative.
Meprin a Metallo RPPGF4-SPFR Expressed normally in intestinal and kidney
(Zn++) (sequence of bradykinin) epithelial cells. cc is secreted or forms a 40
membrane-bound tetramer with subunits.
Elevated levels of meprin observed in colon
Meprin , Metallo YEE,,EEI carcinoma. Degrade ECM.
(Zn ++) SNFD-DY 42
WMi DF
MMP-2 and Metallo Pro-Leu-Gly4Met-Trp-Ser Extracellular proteases overexpressed in a
MMP-9 (Zn++) number of epithelial cancers. Degrade type IV 43
collagen
MT1-MMP Metallo PLPIL Membrane bound enzymes involved in the 44
(Zn++) activation of MMP-2. Found in a number of 45
cancer types. Constitutively activated.
Cathepsin B Cystein RR4- Lysosomal enzymes normally present
FR. intracellularly. Broad substrate selectivity. 47
Secreted or membrane bound for some cancer 48
Cathepsin L Cystein FR4 cells (E.g. Cathepsin B in B16 melanoma and 49
colon carcinoma; Cathepsin L in lung cancer 48
cells) May degrade ECM.
Enabling technologies
To build a polymer-conjugate with a protease-sensitive linker, identifying the substrate
specificity and synthesizing the peptide sequence are two major steps. Examining the natural
substrates can give some information on the consensus sequence. But more direct screening
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methods to yield the optimum sequences have emerged with the advance of experimental tools in
molecular biology and in chemical synthesis.
Matthews and Wells have derived a method, called "substrate phage display", to perform
rapid screening for a large number ( on the order of 107) of protease substrates50 . Using this
approach, peptide substrates have been found for a number of proteases, for example, plasmin51 ,
tissue-type plasminogen activator52, prostate-specific antigen33 and membrane type-1 matrix
metalloproteinase45. This method can be modified to select the optimal sequence for any tumor-
associated enzyme of interest.
The methodology for substrate phage display is illustrated in Figure 1-7. Each phagemid
codes for a phage coat protein, a tether and a protease substrate sequence in between. To create a
phage library, the substrate sequence is randomized by site-directed mutagenesis. Each fusion
protein is displayed on the surface of a phage particle. For screening, the phage particles were
incubated with the protease of interest. The entire digest is then captured by the affinity support.
Phage particles with resistant sequences remain bound via the tether. The tether can be an
epitope for a monoclonal antibody, a histidine tag or a protein-binding peptide. The phage with a
labile peptide sequence is released. The phage with a resistant sequence can be subsequently
released with elution conditions that disrupt the binding of the tether with the affinity support.
Phages with desired sequences, either labile or resistant to the protease of interest, are propagated
in bacteria and the cycle is repeated for enrichment. The incubation condition can be changed to
vary the stringency of the screening criteria. For example, a phage that can be released at lower
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protease concentration or after shorter incubation time displays a substrate sequence that is more
labile.
Coat protein
randomized hexamer
olionentide se tether
I
Non-bound phage
ytyy have protease labile % ,
Capture with affinity support
Phage Library
E. Coli
Enrichment in E.Coli/
Sequence phage clone
Figure 1-7. Illustration of substrate phage display methodology for searching a protease-sensitive
sequence
Chemical synthesis of the peptide sequence has been made more facile with the advance
of solid phase peptide synthesis (SPPS). This methodology was first proposed by Merrifield in
the 1960s53. Since then, this robust process has been improved with automation to allow the
synthesis of peptides of any sequence in a short time without intensive manual labor. The most
commonly employed routine nowadays uses FMOC synthesis sequence. The process flow is
illustrated in Figure 1-8. The keys to the success of the repeated couplings are high step yields
and orthogonal protection groups. In solid phase synthesis, a large excess of reactants can be
used at each chain lengthening step to force a high yield. Unreacted residues can be washed off
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easily. In FMOC synthesis, the FMOC group for protecting the N-terminal is base-labile whereas
the protecting groups on the side chains are acid-labile. The side groups can stay protected
during the addition of a new amino acid to avoid any side reaction. At the end, the entire peptide
sequence is cleaved and all side groups are deprotected using a strong acid.
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Figure I-8. A process flow chart of solid phase peptide synthesis employing FMOC chemistry.
(adapted from www.anaspec.com)
In addition to synthesis of the sequence of interest, SPPS has been used as a tool in
combinatorial chemistry to identify consensus sequences labile to proteases. After generating a
peptide library with SPPS, Turk identified the substrate specificities of various
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metalloproteinases using the methods illustrated in Figure I-9. By keeping scores of all possible
amino acids at each of the substrate positions from P4 to P4', the consensus peptide sequences
were found5 4.
Totally degenerate peptide library:
Ac-XXXXXXXXXXXX
Digest with
protease
IF
Ac-XXXXXX
NH2 -XXXXXX
N-terminal
sequencing
Motif for P positions
(carboxy-terminal to
site of cleavage)
Second generation library:
NH2zMAXXXXXLRGAARE(K-biotin)
protease
N H2 -MAXXXXXLRGAARE(K-biotin)
LRGAARE(K-biotin)
NH2 -MAXXXXX
Immobilized
avidin
NH2-MAXXXXX
N-terminal
sequencing
Motif for P positions
(amino-terminal to
site of cleavage)
Figure I-9. Methodology for identifying protease substrate specificity from a peptide library (The
chart is extracted from reference54)
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CHAPTER II : DESIGN CRITERIA
OF A NEW POLYMER-PEPTIDE-DRUG CONJUGATE
Introduction
We have conceptualized a new polymer-drug conjugate for targeted drug delivery. The
new conjugate is capable of passive targeting due to the appropriate physiochemical properties of
the polymer backbone. The linker of this conjugate has the potential to improve active targeting
via the mediation of enzymes overexpressed in the extracellular space of the diseased tissue. As a
result, the new conjugate acts as a vehicle of drugs that selectively accumulates at the diseased
site and is capable of liberating active drugs in the presence of target enzymes. The conjugate
consists of three parts that are covalently linked: a polymeric carrier, linkers that can be
specifically cleaved the target enzymes, and drug molecules. The schematic of the new polymer-
peptide-drug conjugate is shown in Figure II-1. To illustrate this concept, we will consider the
design criteria for a polymer-peptide-drug conjugate intended for anticancer therapy.
~,222J+`
~IJ.I
Figure II-1. Schematics of the new polymer-peptide drug conjugate
Motivation for Drug Targeting in Anticancer Therapy
Despite advances in the treatment of cancer, approximately 50% of the diagnosed cases
of cancer result in death of patients. According to the estimation of American Cancer Society,
approximately 600,000 Americans are expected to die of cancer in year 2005 (www.cancer.org).
Surgical removal, radiation therapy and chemotherapy are the most common treatment options.
Improving these treatment options will have a major impact on the future of human health.
The treatment option that uses chemicals to inhibit the spread and growth of cancerous
tissues, also known as chemotherapy, has been in use since the 1950s. The application of
chemotherapeutics is efficient in killing cancer cells; however, their activity can also kill normal
cells. When chemotherapeutics are delivered systemically, side effects are commonly seen in the
bone marrow, the hair cells and the gastrointestinal tract. Chemotherapeutics are not specific for
any cell type or tissue. As a result, the dosage and extent of the treatment are limited due to drug-
related toxicity and the effectiveness is compromised. Thus, difficulties in treating cancer partly
stem from inadequate drug targeting. Using rational design, drug delivery devices should be able
to favorably alter the pharmacokinetics of therapeutics favorably and improve the efficacy of
chemotherapeutics. In this thesis research, a novel polymer-drug conjugate containing linkers
cleavable by disease-associated enzymes will be constructed for the tumor-targeted delivery of
chemotherapeutics.
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Polymer selection
The polymer backbone needs to be biocompatible and biodegradable. It should be
hydrophilic, not highly charged, and should have a size above the renal threshold limit to
increase the circulation time. The large size is critical for passive targeting and selective tumor
accumulation by enhanced permeation and retention (EPR). Chemically, it should provide
functional sites to allow covalent attachment to create the conjugate. A number of polymers have
been used in constructing polymer-drug conjugates, for example, HPMA1, PEG2 ,
polyglutamate3 , albumin4 , pullulan5, chitosan6 , dextran7 . Previously, dextran of MW 70,000 Da
was conjugated to doxorubicin via an acid-labile linkage for intratumoral delivery8. We selectd
Dextran T40 and T70 as our polymeric carrier because of its biocompatibility 9 and
biodegradability'°. Dextran, a polymer of glucose, was first approved in 1951 as a 6% solution
for use as plasma expander. Dextran 70/75 was approved by the FDA in 1953 and Dextran 40 in
1967. Its hydrophilic property and its high molecular weight should also allow for passive
targeting l. The glomerular capillaries in kidney are fenestrated, with pores of radii estimated at
20-30nm. Their basement membranes act as a size and charge barrier which appear to hinder the
transport of molecules above 6nm 12. Our light scattering measurements indicate that dextran of
40OkDa (Dextran T40) and 70kDa (Dextran T70) have a mean diameter of 9.9nm and 12.4nm
respectively. These dimensions should lower renal excretion and prolong plasma circulation. The
hydroxyl groups on the dextran backbone provide the necessary sites for covalent modification.
In our design, we want to introduce amine-reactive functional groups to the polymeric carrier so
that it can form a stable linkage with the N-terminal of the peptide linker or the N-terminal of an
intermediate spacer. There are two common methods. In the first method, the hydroxyls are
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oxidized by periodate to become aldehydes. The aldehyde group reacts with an amine to form a
Schiff base. The relatively unstable Schiff base linkage is then reduced by sodium borohydride
or sodium cyanoborohydride to form a more stable alkylamine linkage'3. In the second method,
chloroacetic acid is used to convert a hydroxyl in a base condition to an ether bond ending with a
carboxymethyl group. The carboxymethyl reacts with an amine to form a stable amide linkage13 .
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Linker selection
The new polymer-drug conjugate is designed to take advantage of passive targeting and
EPR effect. Once the conjugate accumulates at the tumor site, we want to explore the possibility
of releasing the drug in the tumor vicinity by tumor-associated enzymes. To investigate this
concept, the linker between the polymer and the drug should be a substrate for an enzyme
overexpressed at the tumor site. We decided to focus on two such enzymes: MMP-2 and MMP-
9. These enzymes are members of the family of matrix-metalloproteinases (MMPs). MMPs are
widely studied enzymes which are secreted in elevated levels in many types of human cancers 14,
15 16 17 18 19. They help the tumor cells to survive and grow by breaking down the extracellular
matrix barrier, releasing growth factors to stimulate cell proliferation and releasing angiogenesis
i-actors to promote blood vessel formation 20
Partly because of the interest in developing specific inhibitors against these enzymes as
anti-cancer therapies, and partly because of the need to develop assays to measure their activities,
their substrate specificities have been extensively studied. Netzel-Arnett examined the
hydrolysis rates on over 50 octapeptides, which represent the systematic variations of a reference
peptide: Gly-Pro-Gln-Gly-Ile-Ala-Gly-Gln2 1 . This reference is modeled after the collagenase
cleavage site in the calf/chick al(I) chain of collagen22 23. The scissile bond is Gly-Ile bond and
this octapeptide covers the P4 through P4' sites (nomenclature according to Schechter &
Berger2 4)The key findings are:
1. Occupancy of P3 to P3' sites is required for rapid hydrolysis
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2. P2 site prefers a hydrophobic residue such as Leu
3. P1 site tolerates only very small amino acid (i.e. Gly)
4. PI' site is conservative. Only substitution of Ile with Met produces a better substrate. A
lot of variations in this site, including Pro, Glu, Ser, Arg and Trp, decrease the hydrolysis
rate significantly.
5. P2'site prefers a large hydrophobic residue such as Trp but also accepts Arg
6. The sequence specificity for MMP-2 and for MMP-9 are similar
Assuming that the change in the reaction rate by each amino acid substitution is additive,
the authors propose Pro-Leu-GlyMet-Trp-Ser-Arg as an optimal synthetic peptide substrate for
MMP-2 and MMP-9, in which the scissile bond is between Gly and Met. (Arg is added to
increase the solubility of the peptide substrate. To prevent hydrolysis by trypsin, D-Arg is used.)
The kinetics for the hydrolysis of the fluorogenic heptapeptide substrate DNP-Pro-Leu-
Gly4Met-Trp-Ser-Arg was measured. At 23°C and pH 7.5, keat/Km = 8900 and 13000 M-1 s-l for
MMP-2 and MMP-9 respectively2 5.
Turk did a more comprehensive search of the optimal oligopeptide substrates for these
enzymes using a combinatorial library 26. The cleavage site motifs of MMP-2 are listed in Table
II-1. He scored all amino acids at each position. His methodology was described in Chapter I. A
score above 1 means that a particular amino acid is preferred at a particular position and a higher
score is associated with a stronger preference. He measured the hydrolysis of the optimal
sequence: Ile-Pro-Val-Ser-Leu-Arg-Ser with the scissile bond between Val and Ser. At 370 C and
pH 7.4, kcat/Km = 82000 and
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11500 M-1s-' for MMP-2 and MMP-9 respectively.
Table II-1. Amino acid preference and its relative score in each
from the screening results of a combinatorial peptide library26
P4
I (1.4)
V (1.3)
P3
P (1.7)
V (1.6)
I (1.5)
P2
V (1.3)
A (1.3)
P1
S (1.9)
G (1.4)
A (1.4)
E (1.3)
P1'
L (4.2)
M (2.8)
I (2.6)
Y (1.9)
F (1.8)
substrate
P2'
R (1.5)
Y (1.5)
1(1.4)
M (1.4)
K (1.4)
position for MMP-2
S (2.2)
G (2.1)
A (2.1)
Our linker sequence is selected from Table II-1. We assumed that the amino acid preference
at each site was independent from the other sites. To simplify the synthesis procedure, we
extracted the best amino acids without reactive side chains. This avoids the problem of having to
dissolve the peptides with bulky protection groups and the degradation of the drug molecule in
the harsh condition during the deprotection step.
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Drug molecule selection
We reason that a non-specific anticancer drug molecule which causes undesirable side
effects upon systemic administration can potentially benefit from the new approach, due to a
better biodistribution of the polymer-peptide-drug conjugate. The drug needs to have a functional
site to attach to the peptide linker. We use conventional chemotherapeutics, doxorubicin (DOX)
as the model drug in our 1st generation conjugate and methotrexate (MTX) in the 2n d generation
conjugate.
DOX is an anthracycline capable of intercalating DNA and thus the drug interferes with
DNA synthesis. The amino ribosyl of DOX is readily available for covalent linkage. This
chemotherapeutic has been used for cancer treatment for many years and is effective against
leukemias, lymphomas, carcinomas of the breast, lung, endometrium, testes, prostate, cervix,
head and neck, and in plasma cell myeloma. In clinical uses, major side effects are associated
with the heart, bone marrow and gastrointestinal tract27. It has been conjugated to a polymeric
carrier made of HPMA 1, dextran 8, albumin2 8 and PEG2 9 via both lysosomal enzyme labile
sequences or acid labile linkages.
MTX is a folic acid analog that inhibits dihydrofolate reductase activity, and thus hinders
the synthesis of RNA and DNA. This molecule has been used for cancer treatment for many
years and is effective against a number of tumors, including lymphoblastic leukemia in children,
chriocarcinoma and related trophoblastic tumors in women, osteosacroma and carcinomas of the
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breast, head, neck, ovary and bladder. Chemically, methotrexate has two carboxyl groups
available for covalent linkage. The limits on the clinical benefits of methotrexate are a result of
the typical problems associated with most conventional chemotherapeutics: short circulation
half-life and undesirable systemic side effects. Like most chemotherapeutics, it is non-specific
and is toxic to all fast growing cells, with major side effects in the gastrointestinal tract and the
bone marrow 27. These problems can potentially be reduced by altering the pharmacokinetics
and biodistribution using the approach of polymer-drug conjugates. Recently, there has been
renewed interest in methotrexate conjugation due to the promising clinical results of albumin-
methotrexate conjugates3 0. Besides albumin, studies of methotrexate conjugate with synthetic
polymers such as poly(ethylene glycol)3 1 and poly N-(2-hydroxypropyl)methacrylamide3 2 have
been carried out by different research groups.
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CHAPTER III: SYNTHESIS AND CHARACTERIZATION OF NEW
POLYMER-PEPTIDE-DRUG CONJUGATES
Introduction
Based on the design criteria described in Chapter II, we set out to synthesize a new
polymer-peptide-drug conjugate. The synthesis process should modify a polymeric carrier
suitable for passive targeting and for enhanced permeation and retention (EPR). The steps should
join the drug molecules to the polymeric carrier via peptide linkers. They should also be
completed without degrading the drug molecules or the peptide sequences. We prepared
carboxymethyl (CM)-dextran-peptide-doxorubicin as the first generation conjugate. There were
three purposes in the preparation of this conjugate: 1) to investigate the stability of the delivery
vehicle under physiological conditions that mimic the general circulation; 2) to examine the
sensitivity of the linker towards MMPs; 3) to find out important aspects for improving the
conjugate in our next design.
The experimental results from the first generation conjugate gave us some feedback on
how to improve the sensitivity of the conjugate towards MMP-2 and MMP-9. We switched the
model drug from doxorubicin to methotrexate because the potency of methotrexate was
potentially more tolerable to the covalent modification on the drug at its gamma carboxyl site .
This change could also facilitate the coupling step between the drug and the peptide. By using a
carboxyl instead of an amino group to conjugate to the peptide linker, the drug molecule can
form an amide linkage with the peptide chain on a solid phase resin (which has an exposed
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amino terminal), thereby simplifying the coupling and the purification steps. In developing the
second generation conjugate, dextran-peptide-methotrexate, we had three goals in mind: 1) to
produce an optimized conjugate capable of releasing drugs by the enzymatic cleavage of MMPs
that is stable in serum containing conditions; 2) to characterize the physiochemical features of
the conjugates; 3) to develop a robust and scalable process in order to prepare materials for
further evaluation in animal studies. In laying out the synthesis route for the second generation
conjugate, we also placed an emphasis on flexibility. The procedures are easily modified to
prepare conjugates with different peptide linkers and different backbone charges. By tuning these
parameters, a polymer-peptide-drug conjugate can be tailored to a wide variety of disease-
associated enzymes.
We describe here the methods to synthesize two generations of dextran-peptide-
chemotherapeutic conjugates. These conjugates were well characterized by various analytical
tools, measuring the product purity, chemical identity, degree of modification of the dextran
backbone, drug loading density and charge potential. Their stability was assessed by size
exclusion chromatographic methods. The rate of drug release in the presence of MMPs was
measured assuming that the enzymatic digestion followed Michaelis Menten kinetics model.
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Experimental Procedures
Materials
Dextran T-40 with a nominal weight of 40,000 Da and T-70 with a nominal molecular
weight of 70,000 Da were ordered from Pharmacia. l-ethyl-3-(3-dimethylamino
propyl)carbodiimide hydrochloride (EDC) and ethanolamine were obtained from Alfa Aesar. O-
B is-( aminoethyl)ethylene glycol trityl resin, 2-(tert-Butoxycarbonyloxyimino)-2-phenyl-
acetonitrile (13 oc-on), I -Hydroxybenzotriazole hydrate (HOBT), (Benzotriazol- -
yloxy)tripyrrolicdinophosphonium hexafluorophosphate (PyBop) and triisopropylsilane (TIS)
vvere obtained from Nova Biochem. Glutamic acid-oa-OtBu was purchased from Bachem.
Trifluoroacetic acid (TFA), dimethylformamide (DMF), dimethylsulfoxide (DMSO), dioxane,
acetonitrile (ACN), ethyl acetate, ether and O1X phosphate buffered saline were obtained from
EM Science. Methanol, sodium chloride and sodium phosphate were from Mallinckrodt. Tris
was purchased from Boehringer Mannheim. Chloroacetic acid, 4-amino-4-deoxy-N °-
methylpteroic acid (APA), benzotriazol-l-yloxytris(dimethylamino)phosphonium (BOP), N-N'-
diisopropylethylamine (DIPEA), diaminopropionic (DPA), 2-Ethoxy-l 1 -ethoxycarbonyl- 1,2-
dihydroquinoline (EEDQ), N.N,N',N'-Tetramethyl-O-(7-azabenzotriazol- 1 -yl)uronium
hexafluorophosphate (HATU), triethylamine (TEA), pyridine, doxorubicin hydrochloride,
methotrexate and calcium chloride and phorbol 12-myristate 13-acetate (PMA) were from
Sigma. Concanavalin A (ConA) was ordered from Calbiochem. mPEG-NHS (methoxy
polyethyleneglycol- N-hydroxysuccinimide ester) of nominal weight of 20,000 was from
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Shearwaters. Peptides were synthesized in the Biopolymer Lab at the Massachusetts Institute of
Technology using standard solid phase techniques and FMOC chemistry (Chapter I).
Purified active human MMP-2 and MMP-9 were purchased from Calbiochem. Precast
protein gels with 10% gelatin and reagents for gelatin zymography were obtained from Biorad.
Plasmocin was ordered from Invivogen. All other cell culture media and reagents as well as
EDTA solution pH 8.0 were ordered from Gibco. Human tumor cell lines HT-1080 and BT-20
were obtained from American Type Cell Culture.
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Synthesis procedures of the 1St generation conjugate: CM-dextran-peptide-doxorubicin
Fmoc peptide
0- C- peptide
+
)oxorubicin
?H3
(iv)
chloroacetic acid
in 6N NaOH/70"C
I Dialysis in H,()
1I
Coupling:
HATU/HOBT in DMF
Deprotection:
piperidmne
HPLC purification:
V .Dac C18/ acetonitrile gradient
peptide NH
, r 0 CH3
O OH O O-CH3
HO' ' 
O= C OH O
CH2-(C)H (i)
Peptide-doxorubicin
+ (v)
Coupling: EEDQ
I
Purification:
size exclusion
Carboxymethyl dexm M-dctran )C-dextran)
degree of substitution of
CM groups -50%7c
(vi)
CM-dextran-pept ide-doxorubicin
Negatively charged
Drug loading- I 
Figure III-1. The reaction scheme for synthesizing the first generation conjugate: carboxymethyl
dextran-peptide-doxorubicin.
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1
Preparation of carboxymethyl dextran (CM-dextran) (structure v, Figure III-1)
This procedure was based on the method by Nogusa for activating pullulan 2. Dextran T-
40 (10g) was dissolved in 100ml of 6N sodium hydroxide solution. Chloroacetic acid (30.2g)
was added to the solution and was held at 700 C for 2--3 hours. Elevated temperature was
necessary for this reaction. The reaction mixture was removed from heat and checked for pH.
Acetic acid was used to neutralize the pH if necessary. The solution was then dialyzed against DI
water using Spectrapor regenerated cellulose membrane with molecular weight cutoff at 3000-
8000 for 2 days at 40C and lyophilized for storage. Degree of carboxymethyl substitution was
determined by analysis of sodium content. Atomic absorption analysis to determine sodium
content was performed by Quantitative Technologies Inc. (Whitehouse, NJ). The degree of
substitution was consistently at 50% (2%).
Synthesis and purification of peptide-doxorubicin (structure iii, Figure III-1)
N-terminal protected FMOC-peptide was condensed with doxorubicin in DMF using
PyBop and HOBT as coupling reagents. Two eq. of FMOC-peptide was mixed with 1.9eq. of
HATU and 6 eq. of HOBT in DMF. After adding 15 eq. of DIPEA, the mixture was reacted with
1 eq. of doxorubicin hydrochloride pre-dissolved in DMF. The reaction was held at room
temperature overnight. The volume of reaction was approximately 0.8mL per 10mg of
doxorubicin hydrochloride. The resulting product was FMOC-peptide-doxorubicin. The FMOC
group was removed by treating in 10%v/v piperidine for 5 minutes at room temperature. The
mixture was then neutralized on ice by a quenching solution containing TFA/pyridine/DMF
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(3:7:20). Peptide-doxorubicin was purified by HPLC on a 20ml C18 preparative scale column
(Grace Vydac, Hesperia, CA) using a gradient from 20-100% acetonitrile with 0.2% TFA. The
organic solvent in the product fractions was removed by rotoevaporation and the purified
material was subsequently lyophilized. Product purity was confirmed to be > 95% and the
amount was quantified by the analytical scale reversed-phase HPLC. The average retention
factor was: 6.24 (pure Dox), 6.57 (IPVG-Dox), 6.90 (IPVGL-Dox), 7.19 (IPVGLI-Dox), 7.19
(-[PVGLIG-Dox ). The identity of the intermediate product was confirmed with mass
spectroscopy: Calc: 910.2 Found: 909.5 (IPVG-Dox); Calc: 1023.5 Found: 1022.9 (IPVGL-
Dox); Calc: 1136.3 Found: 1135.8 (IPVGLI-Dox); Calc: 1193.5 Found: 1192.8 (IPVGLIG-Dox).
Synthesis andl puLrification of CM-dextrtan-peptide-doxorubicin (structure vi, Figure III-1)
To couple peptide-doxorubicin to CM-dextran, peptide-dox (2 [[mole) dissolved in 1:1
D)MF:water (100 g1l) was combined with CM-dextran (10.7 mg) dissolved in 1:1 DMF:water
(200 [t;). EEDQ (33 gmole) was added to the mixture. The reaction was held for 2 hours at
room temperature. The material was purified with a size exclusion column (HR 26/10 column
with Sephadex 75 from Pharmacia) using water as the eluent. After purification, the product was
lyophilized for storage. The product purity was confirmed to be > 99% by the size exclusion
HPLC analytical assay. The drug loading density was estimated by HPLC to be at about 1.0
(mole % per glucose unit).
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Synthesis and purification of PEG-peptide-doxorubicin
Two eq. of mPEG-NHS was reacted with eq. of peptide-dox in the presence of 3 eq. of
DIPEA. ACN was used as the solvent and a volume was used such that the concentration of PEG
was 10% w/v. The reaction was held at room temperature overnight. After the completion of the
reaction, PEG-peptide-doxorubicin was purified by HPLC on a 20ml C18 ptreparative scale
column (Grace Vydac, Hesperia, CA) using a gradient from 20-100% ACN with 0.2% TFA.
The organic solvent was removed by rotoevaporation and the purified material was subsequently
lyophilized. Product purity was confirmed to be > 90% and the amount was quantified by the
analytical scale reversed-phase HPLC.
Synthesis and purification of peptide-cisplatin
Boc-protected diaminopropionic (Boc-DPA) acid was prepared by reacting 1.1 eq. Boc-
on with 0.5 eq. DPA in the presence of 1.5 eq. TEA in 1:1 dioxane/water for 3 hours at room
temperature. Boc-DPA (1 eq.) was then conjugated to the lysine side chain or the amino terminal
of the peptide (.1 eq.) using PyBop (1.5 eq.) in DMF containing TEA (2 eq.) at room
temperature for 4 hours. After drying the solvent, Boc was removed by treating with
TFA/TIS/water (95:2.5:2.5) for 1.5 hours. The intermediate product, peptide-DPA, was purified
by HPLC on a 20ml C18 preparative scale column using a gradient from 0-100% ACN with
0.2% TFA. Potassium tetrachloroplatinate (II) was added in aliquots to peptide-DPA in water.
The reaction was held for 3 hours and room temperature. The final product, peptide-cisplatin,
was purified with a similar HPLC method as above and the platinum content was measured by
inductively coupled plasma analysis, performed at Quantitative Technologies Inc.
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Synthesis procedures of the 2nd generation conjugate: dextran-peptide-doxorubicin
H,N NL ° °S 0t
H2N.N I N O
NH2 O
HO
(i)
peptidN N H-O resin
(ii)
I1A
1lB
1C
0 1T
O NH
(iii)
-N
N N
N NH 2
(iv)
I 2A n
H
H2N
H2N
H2N N,
N NI
NH2
(vi)
(vii)
H2N, N.
NH2
n
Figure 111-2. The reaction scheme for synthesizing the 2nd generation conjugate: dextran-
peptide-methotrexate. Reactants and scales: (i) methotrexate with alpha carboxyl protected
(MTX(OtBu)); typical scale = 1.25mMole MTX equivalent = 2.5 molar excess of peptide. (ii)
peptide on O-Bis-(aminoethyl)ethylene glycol trityl resin (iii ) Jeffamine-peptide-MTX(OtBu);
typical scale= 0.35 mMole MTX eq. (iv) Carboxymethyl dextran with degree of substitution of
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CM groups at -50% and nominal MW 70,000. (v) Ethanolamine. (vi) modified Dextran-peptide-
MTX(OtBu) with degree of modification at -50% and degree of drug loading at -1%; typical
scale = 0. 14mMole MTX eq. (vii) modified Dextran-peptide-MTX with degree of modification
-50% and with degree of drug loading-l%; typical scale = 0.11mMole MTX eq. Reaction
conditions and step yields: 1A: PyBop / HOBT / DIPEA coupling in DMF; B: dilute
trifluoroacetic acid cleavage from resin.; IC: reversed phase HPLC purification; typical yield for
step 1= -70% yield. 2A: coupling with EDC in H20; 2B: charge neutralization by EDC /
ethanolamine in excess; 2C: methanol precipitation; typical yield for step 2 = -40%. 3A: strong
trifluoroacetic acid cleavage to deprotect tert-butyl group from MTX; 3B: diafiltration against
DI water; typical yield for step 3 = -80%.
Preparation of carboxymethyl dextran (CM-dextran) (structure iv, Figure III-2)
This procedure was similar to the preparation of structure v in Figure III- except that
Dextran T-70 instead of T-40 was used as a starting material. The degree of substitution was
consistently at 50% (+2%).
Synthesis and purification of methotrexate-alpha-OtBu (structure i, Figure 111-2)
Methotrexate-alpha-OtBu (MTX(OtBu)) was prepared from 4-amino-4-deoxy-N 0° -
methylpteroic acid (APA) and glutamic acid-o-OtBu using BOP as the conjugating reagent,
following the procedure of Nagy3. Crude MTX(OtBu) was precipitated by centrifugation in a 1:1
mixture of cold ether/ethyl acetate. The material was further purified by HPLC on a 95ml C 18
preparative scale column (Grace Vydac, Hesperia, CA) using a gradient from 0-100% ACN
with 0.2% TFA. The organic solvent in the product fractions was removed by rotoevaporation
and the purified material was subsequently lyophilized. Product purity was confirmed to be >
95% and the amount was quantified by the analytical scale reversed-phase HPLC. The average
retention factor was 6.14.
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Svnthesis of jefftamine-peptide-methotrexate(OtBu) (structure iii, Figure 111-2)
Standard FMOC peptide synthesis in solid phase was carried out on O-Bis-
(aminoethyl)ethylene glycol trityl resins. As in the conventional solid phase peptide peptide
synthesis, the peptide chain grew from the carboxyl to the amino terminals. After the last amino
acid was loaded to the chain, FMOC was removed and the peptide with a free amino terminal
was exposed whereas the carboxyl remained attached to the solid resin via a short 6-carbon
polyethylene oxide spacer.
To couple MTX-uo-OtBu to the amino terminal of the peptide chain, MTX-uo-OtBu (2.5
equivalent to the amount of peptide) was dissolved in DMF containing DIPEA (2.5 equivalent).
PyBop (2.5 equivalent), HOBT (2.5 equivalent) and additional DIPEA (2.5 equivalent) were
used to activate the y-carboxyl of MTX-ot-OtBu for about 15 minutes. More DMF was added
such that the final concentration of MTX-uo-OtBu was about 0.1 M. The mixture was combined
with the resins loaded with peptide and stirred at room temperature overnight. The reaction was
confirmed for completeness the next day by ninhydrin test. Excessive reactants were washed
away from the resins with DMF, DCM and methanol. The resins were then dried thoroughly.
Jeffamine-peptide-MTX(OtBu) was cleaved from trityl resins by suspending the resins in
DCM containing 2% TFA for 10 minutes. This step was repeated 3 times. To collect all the
cleaved product, the resins were further washed with DCM and methanol and the step was
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repeated until no further yellow color was observed (the yellow color was indicative of the
presence of the MTX(OtBu) containing product). Organic solvent was subsequently removed by
rotoevaporation from the collected product. The crude material was resuspended in water and
purified by HPLC over a 0-100% acetonitrile gradient with 0.2% TFA using a 95ml C18
preparative column. Product fractions were lyophilized after the organic solvent was removed by
rotoevaporation. Product purity was found to be > 95% and the amount was quantified by
analytical scale reversed phase HPLC.
The average retention factor on HPLC for MTX(OtBu)-Pro-Val-Gly-Leu-Ile-Gly-
jeffamine was 6.71. Mass spectroscopy confirmed the identity of this intermediate product
(structure iii in Figure 111-2): Calc: 1177.3; Found: 1177.7. [ IH NMR (400 MHz, D20): 6 8.59
(s, H-7 of methotrexate, H), 7.62 (d, 3',5'-H of methotrexate, 2H), 6.81 (d, 2'6'-H of
methotrexate, 2H), 4.86 (s, H-9 of methotrexate, -2H, overlapping with H20), 4.33 (m, Ha of
methotrexate, -I1H, overlapping with H-2 of Pro) 1.8-2.0 (m,H3 of methotrexate, 2H,
overlapping with 3,4-H of Pro), 2.6 (m, Hy of methotrexate, -2H), 1.41 (s, CH3 of tert-butyl,
-9H, overlapping with 3,4-H of Leu), 3.21 (s, CH3-1 of methotrexate, 3H, overlapping with
Jeffamine EDR 148), 3.18-3.74 (m, H of Jeffamine EDR 148, -12H, overlapping with H-5 of
proline and CH3-1 11 of methotrexate), 4.33 (m, H-2 of Pro, - 1H, overlapping with Ha of
methotrexate), 3.87--- 4.35 (m, H-2 of Val, Gly, Leu, Ile, Gly, 7H), 3.4-3.6 (m, H-5 of Pro,
-2H, overlapping with Jeffamine EDR 148), 2.1-2.3 (m, 3-H of Val, 3H of Ile, 2H), 1.8-2.1
(m, 3,4-H of Pro, 4H, overlapping with Ho of methotrexate ), 1.2---1.54 (m, 3,4-H of Leu, -3H,
overlapping with CH3 of tert-butyl), 0.78 - 0.93 (m, 3',4-H of Val, 4'5-H of Leu, 3'4,5-H of Ile,
20H) ]
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The average retention factor of MTX(OtBu)-Gly-Ile-Val-Gly-Pro-Leu-jeffamine on our
reversed-phase HPLC assay was 6.59. Mass spectroscopy confirmed the identity of this
iintermediate product (structure iii in scheme 1): Calc: 1177.3; Found: 1177.1 [1H NMR (400
MHz, DO20): 6 8.59 (s, H-7 of methotrexate, 1H), 7.60-7.62 (d, 3',5'-H of methotrexate, 2H),
6.78-6.80 (d, 2'6'-H of methotrexate, 2H), 4.85 (s, H-9 of methotrexate, -2H, overlapping with
H-O20), 4.35 (m, FIoc of methotrexate, -IH, overlapping with H-2 of Pro), 1.7-2.1 (m, H3 of
mTethotrexate,-2H, overlapping with 3,4-H of Pro), 2.45 (m, Hy of methotrexate, 2H), 1.41 (s,
CH 3 of tert-butyl, -9H, overlapping with 3,4-H of Leu), 3.20 (s, CH3- 11 of methotrexate, 3H,
overlapping with Jeffamine EDR 148), 3.16-3.74 (m, H of Jeffamine EDR 148, -12H,
overlapping with H-5 of proline and CH -11 of methotrexate), 4.35 (m, H-2 of Pro, IH,
overlapping with Hc of methotrexate), 3.84--- 4.25 (m, H-2 of Val, Gly, Leu, Ile, Gly, 7H),
3.3--3.5 (m, H-5 of Pro, -2H, overlapping with Jeffamine EDR 148), 2.1-2.3 (m, 3-H of Val,
3H of Ile, 2H), 1.7-2.1 (m, 3,4-H of Pro, -4H, overlapping with H3 of methotrexate), 1.1--- 1.7
(m, 3,4-H of Leu, -3H, overlapping with CH3 of tert-butyl), 0.74 - 0.88 (m, 3',4-H of Val, 4'5-H
of Leu, 3'4,5-H of Ile, 20H) ]
Synthesis of jeffc!mine-methotrexate(OtBu) (structure iii ', structure not shown)
The procedure was similar to above for the synthesis of (iii) except that no peptide was
loaded onto the resin. MTX-tc-OtBu was directly coupled to O-Bis-(aminoethyl)ethylene glycol
trityl resin using the same protocol. Product found to be > 95% by reversed-phase HPLC. The
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average retention factor ofjeffamine-MTX(OtBu) was 5.81. Mass spectroscopy confirmed the
identity of this intermediate product (iii'): Calc: 640.6; Found:640.6.
Synthesis and purification of Dextran-peptide-MTX (structure vii, Figure 111-2)
To couple jeffamine-peptide-MTX(OtBu) to CM-dextran, jeffamine-peptide-MTX(OtBu)
(0.5 mMol) dissolved in DI water (1.9 ml) was combined with CM-dextran (4g) dissolved in DI
water (6.7ml). EDC (4.7g) was added to the mixture while stirring. The reaction was held
overnight at room temperature. Another aliquot of EDC (4.7g) was added the next day and the
reaction was held overnight to form CM-Dextran-peptide-MTX(OtBu) (structure vi of Figure
III-2).
To block the unreacted carboxymethyl groups on the dextran backbone, ethanolamine
(30ml) was first neutralized to pH 6-7 using 5N HCL in dibasic phosphate buffer on ice. This
mixture was added to (vi) followed by the reaction with EDC (47g). It was held stirring at room
temperature overnight. The modified Dextran-peptide-MTX(OtBu) was precipitated by
centrifugation in methanol.
To remove the protection group OtBu, modified Dextran-peptide-MTX(OtBu) was
resuspended in 40ml strong trifluroacetic acid by vigorous stirring and held at room temperature
for 3 hours. This deprotection step was quenched by diluting the acidic mixture with 0. 1M
phosphate buffer and neutralizing the pH with 5N sodium hydroxide on ice. Extensive
diafiltration was performed using Pellicon XL membrane cassettes of regenerated cellulose with
10,000 MWCO (Millipore, Billerica, MA) to remove excessive reactants and byproducts of the
reaction. After purification, the product in the retentate was concentrated and then lyophilized for
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storage. The product purity was confirmed to be > 99% by size exclusion HPLC. The drug
loading density was estimated by HPLC to be at 1.0 ± 0.2 % (mole % per glucose unit).
Synthesis and purification of Dextran-MTX (structure vii', structure not shown)
This procedure comprised of steps similar to those for the synthesis and purification of
dextran-peptide-MTX (structure vii of Figure III-2), with the exception that jeffamine-
IVITX(OtBu) was used instead of jeffamine-peptide-MTX(OtBu).
Zeta potential measurement
Dextran and dextran-peptide-MTX conjugates were dissolved in DI water at 10mg/ml.
Measurement was performed with Zeta-analyzer (Brookhaven Instruments Co., Holtsville, NY).
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Measurement of kinetics parameters for MMP-2 and MMP-9 digestion of coniugates
The kinetics of enzymatic digestion of the conjugates by MMP-2 and MMP-9 was
modeled by the classical Michaelis Menten equation:
1 1 K m 1
+(
Vi kcat Etotal kct Etotal S'
where Vi is the initial reaction velocity, So is the substrate concentration and Etotal is the
total enzyme concentration, including both bound and non-bound forms. Km is the Michaelis-
Menten constant and kcat is the turnover rate of the substrate-enzyme complex to product. The
ratio kcat / Km is widely used in literature, termed as specificity constant, as a measure of how fast
enzymatic digestion occurs. Conjugates of interest were dissolved in assay buffer (10mM CaC12,
0.2M NaCl in 50mM Tris pH 7.5) at various concentrations: 5, 10, 20, 50 and 1OOAuM. For each
substrate concentration, active MMP-2 or MMP-9 at a final concentration of 10nM was added
and the mixture was incubated at 37C. At specific time points, the reaction mixture was
quenched with EDTA solution at a final concentration of 20mM. The mixture was assayed by 2-
column size exclusion HPLC (assay details are included in the next paragraph) and the cleavage
product peak was quantified to calculate the reaction rate. Initial rate was defined as the rate for
the cleavage of the first 20% of the conjugate. Linear regression was performed on a double
reciprocal plot of l/Vi versus /So to determine the specificity constant kcat/Km.
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HPLC Analytical Methods
Reversed phase analytical assay for online monitoring of process yield and product purity
A silica C18 0.21mmID x 25cmL column (Grace Vydac, Hesperia, CA) was connected to
a HPLC solvent delivery system equipped with a UV detector ( 100 series, Agilent
Technologies, Palo Alto, CA). The method was run at 0.5ml/min with mobile phase A as 0.2%
trifluoroacetic acid (TFA) in water and mobile phase B as 0.2% TFA in acetonitrile. A sample of
10 pL was injected onto a pre-equilibrated column followed by 5 minutes of wash with mobile
phase A. A gradient ramped from 0%B to 100%B in 20 minutes. Detection for doxorubicin-
containing moieties and methotrexate-containing moieties was made by their UV absorbance at
495 nM and 307nM respectively. A calibration curve was constructed correlating the peak areas
-in the chromatograms and the concentrations of the free drugs.
One-columzn size.-excllsion assaclyfr online monitoring of process yield and product purit
A PW3000 7.8mmID X 30cmL column (Tosohaas) was connected to a HPLC solvent
delivery system equipped with a UV detector (Agilent Technologies). The method consisted of
an isocratic elution with 20% ACN and 3.6X phosphate buffered saline in water at 0.8ml/min.
Detection for doxorubicin-containing and methotrexate-containing moieties was made by their
UV absorbance at 495nM and 307nM respectively. The default sample injection volume was set
at 10 gL. A calibration curve was constructed correlating the peak areas in the chromatograms
'~- -'F"I - ~"'~'"" ~"'  "" """"~'" ""~""" cZ = r" ""
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and the concentrations of methotrexate standards. The enzymatic kinetics for polymer conjugate
with bound doxorubicin was also measured with this assay.
Two-column size-exclusion assay for enzyme kinetics study of'dextran-peptide-methotrexacte
A PW3000 7.8mmID X 30cmL column followed by PW2000 7.5mmID x30cmL column
(Tosohaas, Montgomeryville, PA) were connected to a HPLC solvent delivery system equipped
with a UV detector (Agilent Technologies).The method consisted of an isocratic elution with
20% acetonitrile and 3.6X phosphate buffered saline in water at 0.8ml/min. Methotrexate-
containing moieties were detected by their UV absorbance at 307nM or 390nM. The default
sample injection volume was set at 10 jIL. A calibration curve was constructed correlating the
peak areas in the chromatograms and the concentrations of methotrexate standards.
Maintenance of cell culture
Human tumor cells HT-1080 and BT-20 were maintained using DMEM low glucose
media supplemented with 2mM L-glutamine, IX glutamine-penicillin-streptomycin (GPS), 25
[tg/ml plasmocin and 10% fetal bovine serum.
Zymoqraphy of cell conditioned media
HT-1080 and BT-20 were grown to about 70% confluent before the growth media was
exchanged to the serum-free media (DMEM low glucose containing 2mM L-glutamine, IX GPS
and 12.5 ng/ml of PMA) The culture was grown in serum-free media for another three days.
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Cell-conditioned media were analyzed with gelatin zymography according to a previously
described procedure 4.5. Briefly, samples were separated with electrophoresis in a 10%
polyacrylamide gel containing gelatin. After renaturing the gel in 2.5% Triton X- 100 solution, it
was incubated overnight in a development buffer to allow the digestion of the gelatin by MMP-2
or MMP-9. White clear bands in a blue background after Coomassie Blue staining indicated the
presence of the enzymes.
In vitro digestion experiments of conjugates
To assess the stability of the conjugate MTX-PVGLIG-Dextran (PVGLIG is the
shorthand notation of the peptide Pro-Val-Gly-Leu-Ile-Gly) in serum-containing conditions, it
was incubated at 370C and 5% C02 with various media for 24 hours. The percentage cleavage of
the conjugate was determined by the two-column size exclusion HPLC assay.
To demonstrate that the specificity of release of peptidyl drug from the conjugate in cell
culture was MMP-2 and MMP-9 dependent, HT-1080 and BT-20 were grown in 12-well-plates
to about 80% confluent and growth media was exchanged to serum-free media containing
12ng/ml of PMA or 1 Og/ml of ConA. PMA and ConA were used to activate pro-MMP-2 and
pro-MMP-9 to their active forms. After two days, the conjugate MTX-PVGLIG-Dextran was
added to the cell culture and incubated for 6 hours. Media samples were analyzed by two-column
size exclusion HPLC assay to determine the percentage peptidyl drug released from the
conjugate.
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Cytotoxicity assay
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) assay (MTT assay)
was used to measure the drug cytotoxicity according to a previously described procedure with
modifications 6. Cells were seeded in serum-containing growth media to 96-well-plates at 10,000
cells/well. After I day, the growth media was exchanged to serum-free media and the drug
solutions at specified concentrations were added. After another 2 days of drug exposure, MTT
solution was added and the plates were incubated at 370C for 2 hours, followed by overnight
incubation with extraction solution (10% SDS in DMF/H 20 pH 4.7). Plates were read at 570nM
and the readings of the absorbance corresponded to the number of living cells. Percentage
survival was calculated using the formula listed in the website of National Cancer Institute
(http://dtp.nci.nih.gov/branches/btb/ivclsp.html):
[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti Tz
[(Ti-Tz)/Tz] x 100 for concentrations for which Ti < Tz
Where Tz is the reading at time zero prior to the addition of drug solutions, Ti is the
reading at the assay end-point at each of the drug concentration level, and C is reading at the
assay end-point for the control growth ( with no drug addition ).
Growth inhibition of 50 % (GI50) was calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50,
which was the drug concentration resulting in a 50% reduction in the net increase in the number
of viable cells (as measured by MTT assay) compared to control growth.
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Results and Discussion
1 st generation conjugate: CM-dextran-peptide-doxorubicin
Synthesis of the ntlewv conjugates
Following the scheme in Figure 111-1, we successfully prepared the s t generation
conjugate. The synthesis of CM-dextran-peptide-doxorubicin required dextran modification,
solid phase peptide synthesis and coupling techniques in solution phase. To help us monitor and
optimize the synthesis process, we have established a reversed-phase and a size-exclusion HPLC
assay. The dextran polymer, 40 kDa, was modified to carry carboxymethyl groups such that they
can form stable amide linkages with the peptides. Preparative chromatographic methods were
developed to purify the intermediate products and the final conjugates. Analytical HPLC
methods were developed to analyze the conjugate purity, measure its stability and characterize its
drug loadin. Drug loading.  density of the conjugate was about 1% (mole/mole of sugar units).
Empirically, we found that the use of HATU, HBTU or PyBop as the coupling reagent between
the peptide (structure i in Figure III-1) and doxorubicin (structure ii in Figure III-1) could
achieve a significantly higher yield than the more traditional reagent DCC. At first we employed
BOC chemistry in the peptide synthesis. After coupling the protected peptide with doxorubicin,
the BOC group was removed by the treatment with TFA. Dox was degraded in this acidic
environment and this problem was solved by replacing BOC chemistry with FMOC chemistry.
Using HPLC, we confirmed that doxorubicin was stable in 10% piperidine, the deprotection
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condition to remove FMOC. In purifying the conjugate in the last step, we used a size exclusion
column. This method, however, was throughput limited and was therefore difficult to scale up.
To summarize, we learnt some important lessons from the synthesis of the first
generation conjugates: 1) a good choice of coupling reagents is essential to form the amide
linkage between the drug and the peptide; 2) the drug liability in the harsh deprotection
conditions should be tested in the early phase during the development of a synthesis procedure;
3) an alternative purification process is needed for scaling up.
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Stability in serum
To achieve passive targeting, it is important that the conjugate remains uncleaved in the
circulation prior reaching the tumor site. We assessed the stability of the conjugate in the serum
at the physiological temperature (Figure 111-3). Serum alone did not cause any significant release
of peptidyl-doxorubicin from the conjugate.
Figure 111-3. Size-exclusion chromatograms
illustrating the stability of the conjugate
CM-dextran-IPVGLIG-doxorubicin: a)
chromatogram of the conjugate alone prior
the experiment; b) chromatogram of the
fetal-bovine serum alone; c) chromatogram
of the conjugate incubated in fetal-bovine
serum at 37C for 24 hours. No significant
degradation of the conjugate was detected.
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MMP-mediated release is dependent on the peptide sequence
Oligopeptides of 4 to 7 amino acids were evaluated as the peptide linkers (Table
III-1). The sequences were based on the work of Turk7. A combinatorial pool of
octapeptides was screened and the probability of each amino acid at each position was
counted. The optimal sequence determined by this method for MMP-2 was IPVSLRSG.
The presence of the reactive side chains on serine and arginine may pose a problem since
doxorubicin is labile to the acidic conditions required to remove the protection groups put
on these amino acids during solid phase synthesis. As a result, the second best amino
acids with non-reactive side chain were selected in synthesizing the polymer-peptide-
drug conjugate.
Table III-1. Oligopeptide sequences used as peptide linkers in the 1st generation
conjugates. The potential cleavage position for MMP-2 and MMP-9 is between P1 and
P1'
Ile-Pro-Val-.ily
Ile-Pro-Val-Gly--Leu
Ile-Pro-Val-Gly-Leu-Ile
Ile-Pro-Val-Gly-Leu-Ile-Gly
We confirmed the release of peptidyl-doxorubicin from the new conjugates, and
showed that the sensitivity of the linker towards MMP-2 to follow this order: IPVGLIG >
IPVGLI > IPVGL > IPVG (Figure 111-4). The rate of the cleavage depends on the length
of the oligopeptide. After 3 hours, more than 90% of peptidyl-dox was released from
CM-dextran-IPVGLI-dox, less than 15% was released from CM-dextran-IPVGLI-dox ,
and no significant amount of peptidyl-dox was liberated from CM-dextran-IPVGL-dox or
CM-dextran-IPVG-dox. The results were consistent with the reports in the literature
about the necessity to include the optimal amino acids in 3 positions proximal and distal
to the cleavage site ; we concluded that a linker consisting of amino acids from P3' to
P3 should be used in the conjugate of the next design.
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Figure II1-4. Release of peptidyl-doxorubicin from CM-dextran-peptide-doxorubicin
conjugates with different peptide linkers in the presence of MMP-2. Peptide linkers are:
IPVGLIG (*), IPVGLI (e), IPVGL (m) and IPVG (A).Digestion conditions: [MMP-2]
=100nM and [Doxorubicin eq.] = 3.2pM in 50mM Tris, 0.2M NaCl, 2mM CaC12, pH 7.5
CM-dextran backbone interferes with enzymatic drug release by MMP-2
We measured the kinetics of enzymatic digestion of the new conjugate with the
optimal linker, CM-dextran-IPVGLIG-Dox, and compared the result with the peptide-
doxorubicin and the optimal peptide cleavable by MMP-2 (Table III-2). We found that
the specificity constant (kcat / Km) of the CM-dextran-peptide-dox conjugate was two
orders of magnitude lower than the optimal peptide. On the other hand, the value of the
specificity constant of the peptide-doxorubicin was comparable with that of the optimal
peptide. It appeared therefore that covalent attachment to the CM-dextran backbone
caused some hindrance to the enzymatic digestion. Furthermore, the enzymatic cleavage
rate was not lowered when the peptide-doxorubicin was conjugated to methoxy PEG in a
1:1 ratio. There are two differences between CM-dextran and mPEG: 1) CM-dextran
carries a negative charge because of the unreacted carboxymethyl groups, whereas mPEG
is neutral; 2) peptide-doxorubicin is grafted along the dextran backbone (Figure II-1),
whereas the attachment occurred at the terminal end of the long and flexible mPEG
polymer (Figure 111-5). These comparison suggested to us that either the enzymatic
digestion by MMP-2 was affected by the configuration of how peptide-doxorubicin was
tethered to the polymer, or by the electrostatic charge of the polymer.
Table 111-2. Michaelis-Menten specificity constants of MMP-2 sensitive peptide, peptide-
doxorubicin, CM-dextran-peptide doxorubicin and mPEG-peptide-doxorubicin
kcat / Km (M-1 s-1)
Peptide: IPVSLRSG 0.82 x 105 ± 6000 *
1.40 x 10'
Peptide-Dox: IPVGLIG-Dox
Polymer-peptide-Dox: 1.77 x 103
CM-Dextran-IPVGLIG-Dox
Polymer-peptide-Dox: 1.78 x 103
mPEG-IPVGLIG-Dox
"Value obtained from reference7
mPEG polymer Peptide-doxorubicin
Figure 111-5. Schematic representation of mPEG-peptide-doxorubicin
If the negative charge on the carboxymethyl-dextran backbone poses a
electrostatic repulsion between the conjugate and MMP-2, we should observe a
phenomenon consistent with Debye-HUckel theory, which states that:
log (k/ko) = 1.018 ZAZB I
where k is the rate constant at ionic strength I, ko is the rate constant at zero ionic
strength, ZA and ZB are the charges of the reactants.
If ZA and zB have the same signs, the theory predicts that as ionic strength in the
digestion environment increases, the kinetics of the cleavage improves. This is because
the charges of the reactants are more efficiently screened by the media. We observed this
trend in a salt titration experiment (Table 111-3) and concluded that the electrostatic
repulsion between CM-dextran and MMP-2 significantly hampered the enzymatic
digestion. As a result, we decided to experiment with blocking the excessive negative
charge on the CM-dextran backbone in the next design.
Table 111-3. Effect of salt concentration on the rate of enzymatic digestion of the
conjugate CM-dextran-IPVGLIG-doxorubicin. The assay buffer contains 50mM Tris,
2mM CaC12, pH 7.5 and varying amount of NaCl as indicated.
Salt concentration kcat/ Km (M ' S '1 )
(Molar of NaCl)
in assay buffer
0.01 7.50 x 10l
0.1 1.15 x 102
0.2 1.09 x 103
0.5 4.47 x 103
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Cytotoxicity of doxorubicin is neutralized by amino acid attachment
The product released by MMP-2 from the most sensitive 1 t generation conjugate,
CM-dextran-IPVGLIG-dox,was confirmed by mass spectroscopy to be LIG-Dox (Calc:
826.8, Found: 826.1). The potency of cytotoxicity of doxorubicin dropped by two orders
of magnitude when LIG was covalently attached the drug (Figure 111-6). This is probably
because the ribosyl amino group on doxorubicin participates in the hydrogen bonding
with the intercalated DNA. Thus the blocking of this group reduces the drug's efficiency
in inhibiting DNA replication.
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Figure 111-6. Comparison of cytotoxicity of free doxorubicin () and Leu-Ile-Gly-Dox
(-) on HT-1080 fibrosacroma culture. LIG-Dox is the product released from CM
dextran-IPVGLIG-Dox by MMP cleavage.
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This prompted us to investigate the possibilities of other drug candidates: cisplatin
and methotrexate (Figure III-7). The literature contained information about their
structure-activity-relationship which suggested possible modifications without the
sacrifice of the drug potency'. Analogs of peptide-coupled drugs, which represent the
possible cleavage products by MMP digestion, were compared with free drugs for their
cytotoxicity ill cell culture (Figure 111-8). The results from cisplatin were disappointing,
showing a complete neutralization of the drug potency with peptide attachment. The
results of methotrexate were more promising, though the peptide attachment still reduced
drug activity. We decided to use methotrexate as the next drug candidate, also because its
gamma-carboxyl group is available for coupling and should allow us to attach the drug to
the peptide with a more facile method (further discussed in the synthesis of 2 nd generation
conjugate).
NH F CH3 O
H2 I I!
IN-CH-C-
H,N N H H 3N Cl
CH,
IH-CH,
C O
OH
Figure III-7. (hemical structure of metotrexate (left) and cisplatin (right)
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Figure III-8. Comparison of cytotoxicity of free drug and peptide-drug of methotrexate and
cisplatin: a) methotrexate [,], MTX-PVG [m], MTX-IPVG [A] and LK(MTX)G [x]; b)
cisplatin [x], cisplatin-PVG [ ], LK(cisplatin)G [m] and LIGK(cisplatin) [A].
2 nd -qeneration conjuqate: dextran-peptide-methotrexate
Synthesis of the new conjugates
We have developed a robust, adaptable and scalable process to prepare the 2 nd generation
conjugate. The process flow chart for synthesizing and purifying dextran-peptide-methotrexate
conjugates is shown in Figure III-2. The reversed phase and size exclusion HPLC assays used for
analyzing the Ist generation conjugate were modified to analyze the 2 nd generation conjugate.
10 100
The drug molecule to be attached to the new conjugate, methotrexate, has some bulk
tolerance at the y-carboxyl group. It is important that the oc-carboxyl, the less tolerable functional
group, is protected throughout the synthesis process. Thus methotrexate-alpha-(OtBu) (structure
i, Figure III-2) was prepared from APA. This protected methotrexate was first conjugated to the
peptide in a solid phase reaction. Trityl resins were chosen as the solid-phase supports since the
products synthesized on the resins could be released using a dilute acid thus leaving the tert-butyl
group on methotrexate unaffected. This protection group was eventually removed in the last
reaction step (step 3A, Figure 111-2).
We have combined solid phase and solution phase synthesis to make the process more
flexible. Peptide synthesis on solid supports is now a highly automated process and peptide
sequences of varying length or composition can be readily prepared in a short time (Chapter I).
The advance of this current technology lets us readily accommodate any change in the peptide
sequence as the conjugate's linker. This is valuable when we expand the current approach to
target other tumcor-associated enzymes, which are made up of a diverse group of proteases. A
few examples include prostate-specific antigens , urokinase-type plasminogen activator 10 and
cathepsin-L . On the solid support, the peptide chain grows from the carboxyl terminal and a
free amino terminal is exposed after the last prolongation step. Since methotrexate has a gamma-
carboxyl, it can be covalently joined to the amino end of the peptide in a solid phase reaction
(step 1A, Figure 111-2). Using an excess amount of reactants is feasible and this enables the
conjugation step to have high yield. Afterwards, the unreacted species can be washed off while
jeffamine-peptide-methotrexate remains attached to the solid support. This results in a reasonable
purity of the intermediate product (structure iii, Figure 111-2).
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We have chosen a special trityl resin, O-Bis-(aminoethyl)ethylene glycol trityl resin
(structure ii, Figure 111-2), as the solid support. This enables the peptide to be attached to
jeffamine, a short polyethylene oxide chain. After detaching from the solid support, the peptide
remains attached to jeffamine. Jeffamine aids in the coupling between the peptide-drug and
carboxymethyl dextran (structure iv, Figure 111-2). Our MMP-recognizable peptide sequence is
composed of hydrophobic amino acids (Pro-Val-Gly-Leu-Ile-Gly). The protected drug MTX-ot-
(OtBu) also has limited aqueous solubility. On the other hand, carboxymethyl dextran is
hydrophilic. In our attempts to couple peptide-drug to carboxymethyl dextran in the presence of
EDC, we have found that the concentration of the amine component and the concentration of the
carboxyl component are critical factors in determining conjugation yield.
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Table I-4 lists ithe conjugation yield when we varied the amine or the carboxyl concentration in
the coupling step, keeping all other reaction conditions identical. This observation is explained
by the relatively short half-life of the EDC-activated carboxyl. If unable to encounter an amine
component for reaction, the active ester becomes inactivated 12.Because of the hydrophilic
character of the jeffamine spacer that improves aqueous solubility, higher concentration of
jeffamine-peptide-MTX(OtBu) (structure iii, Figure III-2) can be attained and the conjugation in
aqueous phase results in a reasonable yield (Step 2A, Figure I-2).
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Table 111-4. Conjugation yield of the reaction step between carboxymethyl dextran and
jeffamine-peptide-MTX(OtBu), varying the amine and the carboxyl concentration
Amine concentration (M) Carboxyl concentration (M) Conjugation yield (%)
0.02 0.66 76
0.02 0.18 41
0.02 0.09 29
0.02 0.02 15
0.01 0.66 25
Stability in serum-containing conditions
Our new conjugates are intended for systemic delivery. To be able to passively target the
tumor sites and achieve enhanced permeation and retention, the conjugates must remain stable in
the blood circulation and the drug molecules should stay attached to the polymer backbone prior
reaching the tumor tissues. We used fetal bovine serum and serum spiked with active human
MMP-2 and MMP-9 to approximate the physiological conditions encountered by the conjugates
in systemic circulation. The MMP addition was intended to mimic the circulation environment
when tumor growth is present in the body. When tumor tissues overexpress MMP-2 and MMP-9,
the enzyme levels are also elevated in the blood stream 3. However, protease activities of these
MMPs in the systemic circulation are greatly reduced because of the inhibition by serum
proteins. One of these inhibitors is uo2-macroglobulin, a large serum protein with molecular
weight of about 800kDa that offers the proteases a bait region. Once the bait region is cut, or2-
macroglobulin changes shape to entrap the MMP 14. We demonstrated that the conjugates were
satisfactory in meeting the stability criteria(Figure 111-9). While the conjugate MTX-PVGLIG-
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Dextran was sensitive to MMP-2 or MMP-9 in assay medium that was serum free, releasing a
significant amount of peptidyl methotrexate, it remained uncleaved in the serum. This inhibitory
effect of the serum on MMP activity was also evident. There was no significant release from the
conjugate in the serum spiked with same concentrations of MMPs.
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Figure 111-9. Stability of conjugate MTX-PVGLIG-Dextran in various media conditions.
Conjugates were incubated with the specified conditions for 24 hours at 370 C and assayed by
size exclusion HPLC to determine the percentage cleavage of the conjugate. The conjugate
released peptidyl drug in serum-free conditions but remained intact in all the serum-containing
conditions. The average values from 3 replicates with standard deviations as error bars are
shown.
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MMP-mediated drug release requires an optimized peptide linker
We have prepared three different conjugates: 1) MTX-PVGLIG-Dextran, with the
peptide linker composition optimized for MMP-2 recognition; 2) MTX-GIVGPL-Dextran, with a
scrambled peptide linker; 3) MTX-Dextran, without a peptide linker. The extents of drug release
from these conjugates in the presence of MMP-2 and MMP-9 were compared in Figure HI-10
and Figure III-11.
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Figure m-10. Extent of methotrexate equivalent released from different conjugates in the
presence of MMP-2. Conjugates of different linkers were incubated with 10nM of MMP-2 in
assay buffer at 370C and measured for percentage cleavage at specified time points by size
exclusion. Peptidyl methotrexate analogs were the expected products released from the dextran-
peptide-methotrexate conjugates upon cleavage. Methotrexate was the expected product released
from the dextran-methotrexate conjugate upon cleavage. Cleavage of the conjugate by MMP-2
was dependent on the linker composition.
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Figure III-1 1. Extent of methotrexate equivalent released from different conjugates in the
presence of MMP-9. Conjugates of different linkers were incubated with 10nM of MMP-9 in
assay buffer at 370C and measured for percentage cleavage at specified time points by size
exclusion. Peptidyl methotrexate analogs were the expected products released from the dextran-
peptide-methotrexate conjugates upon cleavage. Methotrexate was the expected product released
from the dextran-methotrexate conjugate upon cleavage, if any. Cleavage of conjugate by MMP-
9 was dependent on the linker composition.
Similar trends were observed for both MMP-2 and MMP-9. MTX-PVGLIG-Dextran
conjugate released 89% of peptidyl methotrexate in the presence of MMP-2 and 61% in the
presence of MMP-9 after 24 hours. In contrast, conjugates without any peptide linker or carrying
the scrambled peptide linker did not show any significant release. Without the MMP
recognizable peptide linker, the conjugate was stable even in the presence of a high
concentration of MMP-2 or MMP-9. We isolated the small molecular weight cleavage product
from the digest of MTX-PVGLIG-Dextran on size exclusion column and analyzed the product
fraction by mass spectroscopy. The molecular weight found was 707.5 and was consistent with
the notion that methotrexate-Proline-Valine-Gly (MTX-PVG) was the released product. This can
be predicted by the scissile site of MMP-2 and MMP-9 on the peptide7 .
We want to explore the possibility of releasing the active drug molecules from the
conjugates in the presence of the tumor-associated enzymes MMP-2 and MMP-9. A peptide
linker labile to the enzymatic digestion is important to achieve this purpose. For the optimal
linker, we selected the most preferable amino acids with non-reactive side chains from Turk's
work 7 to fill the substrate positions from P3 to P3'. From our experience in the 1St generation
conjugate, these six positions are necessary for the recognition by MMP-2. We showed that the
cleavage of the new dextran-peptide-methotrexate conjugate depended on the composition of the
peptide linker. Although PVGLIG shows a high cleavage rate by MMP-2 and MMP-9, this
peptide is not sensitive exclusively to these two enzymes. Because of the similarity among
members in the family of matrix-metalloproteinases 7,14 , this peptide is expected to be cleavable
by other MMPs albeit with lower rates.
Preparation of conjugates with varying backbone negative charges
To investigate the effect of the net charge on the dextran backbone, we prepared different
conjugates by reacting the excess carboxymethyl with ethanolamine using different conditions.
Ethanolamine is a simple, neutral and hydrophilic molecule (structure v and step 2B, Figure
111-2). The charges on the resulting conjugates were characterized by its zeta potential. We first
experimented with just carboxymethyl dextran (structure iv, Figure 111-2) and found that the
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negative charge could be partially or fully neutralized using appropriate reaction conditions
('Table 111-5). We have therefore devised a method to modify the magnitude of the negative
charge on the dextran backbone, a factor other than the peptide composition that can be tailored
to different enzymes of interest for optimizing conjugate sensitivity.
Table 111-5. Zeta potentials of dextran and modified dextran samples
Sample Zeta potential (mV)
Dextran T70 (neutral) -6.6
Carboxymethyl dextran CM-Dextran -47.4
(degree of substition -50% determined by atomic
absorption sodium analysis)
Ethanolamine neutralized CM-Dextran A -36.25
(EDC at 2 fold excess and ethanolamine at 10 fold excess
of glucose units present on dextran)
Ethanolamine neutralized CM-Dextran B -1.06
(EDC at 10 fold excess and ethanolamine at 20 fold excess
of glucose units present on dextran)
By tuning the amount of EDC and ethanolamine, we prepared MTX-PVGLIG-Dextran
conjugates with varying negative charges and examined the charge effect on the kinetics of
digestion by MMP-2 and MMP-9 (Table 111-6). Recall that in our experience with the 1St
generation conjugate, we observed that the rate of MMP-2 cleavage increased with higher ionic
strength in the digestion media. In accordance with Debye-Htickel theory, we reasoned that this
phenomenon could be explained by the electrostatic repulsion between the enzyme and the
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negatively charged conjugate. Here, we confirm this hypothesis by showing that the charge on
the conjugate backbone has a significant effect on the rate of MMP-2 cleavage. The value of
kcat/Km is varied by an order of magnitude depending on the charge. The conjugate most
sensitive to MMP-2 (Conjugate C) has its excess carboxymethyl groups completely masked by
ethanolamine and is neutral in charge. It has a similar kinetics constant towards MMP-2
digestion as the optimal peptide found by Turk7 . (In his report, Ile-Pro-Val-Ser-Leu-Arg-Ser was
reported to have a kcat/Km value of 0.82E5 M-ls-.) On the other hand, the kinetics of enzymatic
digestion by MMP-9 was much less sensitive to the charge difference on our conjugate
backbone. Taken together, the conjugate with its carboxymethyl groups masked and hence least
negatively charged has the highest sensitivity towards MMP-2 and MMP-9.
Table 111-6. MTX-PVGLIG-Dextran conjugates with varying negative backbone charge show
significantly different sensitivity towards MMP-2 cleavage but similar sensitivity towards MMP-
9
Conjugate Backbone negative Zeta kcat/Km (M- s- ) kcat/Kmn (M-1 s1)
I.D. charge masked with potential
ethanolamine? (mV) by MMP-2 by MMP-9
digestiona digestion b
A None -43.7 2.12E4 + 3.33E2 7.09E3 + 5.52E2
B Partially -27.8 1.10E4 + 9.66E2 3.09E3 ± 5.04E2
C Fully -12.2 1.21E5 + 4.11E3 3.60E3 + 4.14E2
ab The average values and standard deviations of 3 replicates are reported
The difference in charge effect on MMP-2 and MMP-9 digestion kinetics is interesting
considering that these two enzymes are very similar in structure. Both have three repeats of
fibronectin type II domain ~4. Categorized together as gelatinases, they are also reported to have
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similar biological substrates and specificity 8.We compared the amino acid sequences of the
active form of human MMP-2 and MMP-9, taken from the Swiss-Prot database (P08253 and
P14780 for their precursors). The net charge of MMP-2 is 10 times more negative than MMP-9.
This discrepency is consistent with our current experimental observation that MMP-2 exhibits
significantly more electrostatic repulsion towards the negatively charged dextran backbone.
Specificity of release in tumor cell culture
HT-1080 is a human fibrosacroma cell line that is known to express MMP-2 and MMP-9.
BT-20, a human breast cancer cell line, expresses a lower amount of MMP-2 compared to HT-
1080 and has no detectable level of MMP-9. These features were confirmed by zymography of
the cell conditioned media from these cell lines (Figure 111-12). In HT-1080 cell conditioned
media, prominent bands are observed at at 92kD, 86kD, 72kD and 68D. These molecular weights
are consistent with the values of latent MMP-9, active MMP-9, latent MMP-2 and active MMP-2
respectively. In BT-20 conditioned media, only a faint band is present at 72kD indicating a
relatively small amount of latent MMP-2.
Figure 111-12. Gelatin zymography of HT-
1080 and BT-20 cell conditioned media. The
white bands in the dark backgrounds
indicate the presence of MMPs. Latent and
active MMP-2 (72kD and 68kD) and latent
and active MMP-9 (92kD and 86kD) were
expressed by HT-1080. Only a faint band of
pro-MMP-2 (72kD) was found in BT-20.
All conditioned media samples were
normalized to the same cell number.
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The conjugates MTX-PVGLIG-Dextran were incubated for 6 hours with these two types
of cell culture. The digest showed no detectable cleavage of the conjugates in BT-20 culture. In
contrast, 14% cleavage was observed in HT-1080 culture (Table 111-7). The in vitro experiments
provided evidence that the conjugates were able to be cleaved in the tumor culture and the
extracellular release of peptidyl drug was due to the presence of MMP-2 and MMP-9. In these
cell cultures, no serum was present. The absence of serum protein was intended to mimic the
conditions in the tumor vicinity in vivo. Because of the large sizes of the serum protease
inhibitors such as c2-macroglobulin, they are unable to cross the capillary endothelium and
therefore are absent in the interstitial fluid. In the tumor tissues, the activities of MMP-2 and
MMP-9 are not inhibited by serum proteins although they are regulated more specifically by
tissue inhibitors of metalloproteinases (TIMPs) 14
Table 111-7. Susceptibility of the MTX-PVGLIG-Dextran conjugate to cleavage in tumor cell
conditioned media
Cell culture Expression of Expression of Percentage cleavage of
active MMP-2 active MMP-9 the conjugatea
HT-1080 +++ +++ 14.2% 0.07%
BT-20 + None detected
a The average value of 2 experiments and the standard deviation are reported
Cytotoxicity of the released peptidyl drugs towards tumor cells
Because of the requirement of P3 to P3' sites for substrate recognition by MMP-2 and
MMP-9, the released product from the conjugate contains three amino acids attached to the free
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drug. Although methotrexate exhibits some bulk tolerance at the gamma-carboxyl site, we are
concerned about the therapeutic effect of the released product. The released product from the
new conjugate is a peptidyl methotrexate analog (MTX-PVG). The cytotoxicity of MTX-PVG
was measured and compared with free methotrexate using MTT assay. For both tumor cell lines,
HT-1080 and BT-20, peptidyl methotrexate was cytotoxic with GI50 on the order of 10lOM.
Compared to free methotrexate, the potency of the drug was lowered by two orders of magnitude
(Figure 111-13).
Cytotoxicity assays showed that the released product was still effective in inhibiting the
proliferation of tumor cells but the potency was lower than the free methotrexate. This is the
biggest concern of the current approach, namely, the drug is not released in the original free
form. However, the loss in cytotoxicity in vitro may not translate to the loss in anti-tumor
efficacy in vivo. The capability of remaining stable in the systemic circulation, as well as the
sensitivity of the new conjugates to the tumor-associated enzymes MMP-2 and MMP-9, suggest
that the new conjugates can passively target the tumor tissue and potentially have localized drug
release by MMPs. We predict that these qualities will improve both the circulation half life of the
conjugate and the percentage dose accumulated in the tumor tissue. While these effects can bring
about improvement in anti-tumor efficacy in vivo but cannot be measured in cell culture assays,
further investigation in animal models is warranted.
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Figure E-13. Cytotoxic effect of methotrexate and methotrexate-Pro-Val-Gly by MTT
assays on cell culture: a) HT-1080 and b) BT-20. The average values of 3 replicates with
standard deviations as error bars are shown.
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CHAPTER IV : IN VIVO ANTI-TUMOR EFFICACY OF NEW
DEXTRAN-PEPTIDE-METHOTREXATE CONJUGATES
Introduction
We have developed and characterized a new conjugate that is stable under
physiological conditions and is capable of drug release by the enzymatic digestion of
MMPs. The ultimate goal of this conjugate is to achieve targeted drug delivery to the
tumor site, resulting in an improved anti-tumor efficacy and decreased systemic side
effects. Although in vitro models provide convenient settings for experimentation, with
well defined and controllable variables, they lack the complexity of the actual disease
environment. Furthermore, we intended our design to favorably alter the
pharmacokinetics and biodistribution of the chemotherapeutics. These potential benefits
can only be observed in an in vivo model, in which tissues are interconnected and
mechanisms are in place for drug clearance and metabolism. In the field of polymer-drug
conjugates, it has been emphasized that in vivo but not in vitro results are useful as basic
indicators of any clinical potential. Some published records of polymer-drug conjugates
in treating tumor-bearing animals are listed in Table IV-1. These findings can be used as
a benchmark for gauging our in vivo results.
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There are three main goals in our in vivo studies: 1) to measure the anti-tumor efficacy of
the new conjugates and compare the results to the free drugs; 2) to evaluate drug-related side
effects in normal tissues; 3) to estimate the role of MMP-mediated release in the targeting ability
of the new conjugate. For these purposes, we performed experiments in three tumor-bearing
mouse models: HT-1080, U-87 and RT-112. RT- 112 contrasted the other two models by its lack
of MMP-expression. The MMP-sensitive conjugate, MTX-PVGLIG-dextran, was compared with
free methotrexate and the MMP-insensitive conjugate, MTX-GIVGPL-dextran, at an equivalent
dosage. The two forms of conjugates are similar, differing only by the peptide sequences in their
linkers.
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Materials and Methods
Materials
Methotrexate was purchased from Sigma-Aldrich. The two conjugates, MTX-PVGLIG-
dextran and MTX-GIVGPL-dextran, were synthesized and purified as described (Chapter III) 7.
The four methotrexate-peptide analogs: MTX-G, MTX-GI, MTX-GIV and MTX-PVG were
prepared using the reported methods with slight modifications: 1) different amino acid sequences
were synthesized on the solid-phase resins and 2) the HPLC purification of these methotrexate-
peptide analogs was performed on a smaller 20mL column. Human tumor cell lines HT-1080
and U-87 were grown from seed vials purchased from American Type Cell Culture. RT-112 was
a gift from Dr. Marsha Moses at the Children's Hospital (Boston, MA). The cell lines were
maintained as described (Chapter III) 7 and tested negative for murine pathogens and
mycoplasma prior being used in animal study.
Animal Models
Six-week old female SCID mice were obtained from Charles River Laboratory. Animal
studies were conducted in accordance with an approved protocol by the Department of
Comparative Medicine at the Massachusetts Institute of Technology. One to two million tumor
cells were injected subcutaneously at the mid-dorsal level. Treatment was initiated after the
tumor was allowed to grow to about 100 mm3on the back of the mouse. This experimental
protocol is intended to mimic the clinical situation when treatment begins after a tumor has
already been established in a patient. Free methotrexate, MTX-PVGLIG-dextran and MTX-
GIVGPL-dextran were injected intraperitoneally (i.p.) once a week. The dosage was normalized
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according to the body weight of the mouse. In the control group, each mouse was injected with
0.5mL of phosphate buffered saline. Up to three injections were performed for HT-1080 and RT-
112 and two injections for the fastest growing U-87. For all three models, the groups receiving
MTX-GIVGPL-dextran were sacrificed after the first injection because of severe weight loss.
Weight and tumor size were monitored three times a week. Tumor size was calculated with the
formula: size = width- x length x 0.52.
Histology and Immunochemistry
Tissues were fixed in 10% buffered formalin overnight, and were processed for paraffin
embedding and sectioning using standard histological procedures. For bone marrow sections,
femurs were decalcified after fixation. Tumor sections were stained with hematoxylin and eosin
for general morphologic evaluation, with MMP-2 and MMP-9 antibodies for the expressions of
the two enzymes, with Ki67 for proliferating cells, and with CD34 for blood vessels.
Preparation of Tumor Extract and Measurement of MMP concentrations
The procedure of preparing tumor extract was adopted from the Moses Laboratory at the
Children's Hospital (Boston, MA) 8. Samples of dialyzed tumor extract were analyzed for their
MMP-2 and MMP-9 concentrations using ELISA kits (Calbiochem) according to the
manufacturer's instructions. Gelatin zymography of the tumor extract was performed as
described in Chapter III.
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Results
Design of animal study
We used subcutaneous tumor models in mice for the in vivo studies. These types of rodent
models are most common in literature, as exemplified in Table IV- 1, and they can be readily set
up. Since our design and characterization of the conjugates are associated with human-form
MMPs, we selected three tumor cell lines of human origin: HT-1080 human fibrosacroma, U-87
human glioblastoma and RT-112 human bladder tumor. HT-1080 and U-87 are known to
overexpress MMP-2 and MMP-9 9-12. RT-1 12 was selected to contrast the other two cell lines by
its absence of MMP overexpression to assess whether the treatment efficacy of the new
conjugate would depend on the expression of MMP in the tumor model. The level of enzyme
expression of the tumor lines were assessed in cell-conditioned media using gelatin zymography
(data not shown) and in in vivo tumor extracts by ELISA (Table IV-2). The concentration of
MMP-2 was 10-fold higher and the concentration of MMP-9 was 50-fold higher in HT-1080 and
U-87 tumors than in the RT-112 tumor. Immunohistochemical staining of tumor sections
harvested from the mice also indicated that HT-1080 and U-87 were MMP-2 positive and RT-
112 was MMP-2 negative (Figure IV-1). MMP-9 staining was positive for all cell lines but the
staining was significantly weaker in RT-112 (Figure IV-2).
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Table IV-2. ELISA measurement of MMP-2 and MMP-9 in extracts from tumors harvested from
the three mice tumor models
HT- 1080 U-87 RT-112
MMP-2 concentration 17.0 ±6.3 16.1 ±12.4 1.5 ±1.1
(ng/ml)
MMP-9 concentration 5.2 ±1.7 5.0 ±1.0 0.1 ±.01
(ng/ml)
Figure IV-1. Tumor sections harvested from tumor-bearing mice stained against MMP-2
antibody. a) HT-1080; b) U-87; c) RT-112. Brown coloration indicates that the presence of
MMP-2.
Figure IV-2. Tumor sections harvested from tumor-bearing mice stained against MMP-9
antibody. a) HT-1080; b) U-87; c) RT-112. Brown coloration indicates that the presence of
MMP-9.
Although we used BT-20 to investigate the in vitro properties of the conjugate in the
absence of MMP over-expression, we did not complete the in vivo study with this cell line. We
performed one preliminary experiment in BT-20 bearing mice but later observed that the tumor
model could not be established reproducibly. The problem failed to be resolved by implanting
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more tumor cells, restarting cell passage from existing seeds, or using fresh new seeds from the
source company. At that point, we decided to use RT- 112 as our best alternative.
Pilot studies were performed in HT-1080 bearing mice to assess the maximum safe dose
of the free drug and the conjugate (MTX-PVGLIG-dextran), which was 50mg/kg/week; the
results are summarized in Table IV-3. Three weekly dosages were injected by the end of the pilot
study when the tumor burden reached the maximally bearable size in the control group. The mice
in the conjugate group had slightly more weight loss compared to the saline-treated control group
but generally remained healthy and active. The conjugate did not cause any toxic death at this
dosage whereas free methotrexate caused an average about 20% death rate for two pilot studies.
There was more variability in the death rate in the free methotrexate-treated group, which could
not be attributed to drug-related toxicity with full certainty because symptoms such as severe
hypoactivity and sharp weight loss were absent. In addition to the weekly injection study, a
twice-weekly dosing study was performed with 50mg/kg free methotrexate or MTX-PVGLIG-
dextran. Doubling the injection frequency resulted in severe and acute toxicity in both treatment
groups, so the subsequent studies were carried out with weekly injections of 50 mg methotrexate
eq./mouse body weight and a maximum of three injections were administered.
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Table IV-3. Tolerance of tumor bearing mice on different dosage regimes of free methotrexate,
dextran-methotrexate and dextran-peptide-methotrexate found in pilot studies
i.p. dosage per week % weight drop at Number of deaths
Dosage form (mg methotrexate eq. the end of the due to drug-related
/kg of mouse body weight) study toxicity
12.5 8% 0/3
25 20% 0/3
Free methotrexate
50 16%;15% 2/5*;0/5
100 24% 0/4
6.25 13% 0/4
MTX-dextran 12.5 16%; 12% 1/3; 0/3
conjugate 25 19% 3/3**
50 27% 3/3**
12.5 1% 0/3
MTX-PVGLIG- 25 12% 0/3
dextran conjugate 50 13%; 10% 0/3; 0/4
100 19% 3/4 **
Saline control 0 3%;11%;8%;9% 0/3;0/3;0/3;0/3
* deaths are of unknown causes; drug-related toxicity was suspected
** only 2 weekly injections were performed because of severe toxic response and serious weight loss
In the pilot study, we noted an unexpected phenomenon with MTX-dextran though this
dosage form would not be used in the subsequent efficacy study. The maximum tolerable dosage
for this conjugate was 12.5mg/kg, 4 fold lower than free methotrexate. Without a peptide linker,
we did not expect this conjugate to be cleavable. However, the severe toxicity observed at
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25mg/kg, in contrast to the mild weight drop (10-13%) in MTX-PVGLIG-dextran treated group,
suggested that there was release of active methotrexate from MTX-dextran.
For the anti-tumor efficacy study, we decided to use MTX-GIVGPL-dextran instead of
MTX-dextran to contrast the targeting conjugate MTX-PVGLIG-dextran. MTX-GIVGPL-
dextran bears more similarity to MTX-PVGLIG-dextran. They are identical apart from the order
of the amino acids in the peptide linkers. The difference in their sensitivity towards MMPs would
let us explore the role of the enzymes in the targeting capability of the conjugates.
In summary, we concluded that the subsequent efficacy and side-effect studies would be
performed in HT-1080, U-87 and RT-112 bearing mice. The three dosage forms: free
methotrexate, MTX-PVGLIG-dextran, MTX-GIVGPL-dextran would be compared at equivalent
dosage of 50mg methotrexate eq./kg of body weight. This dosage would be administered via i.p.
injection on a weekly basis up to three times. Phosphate-buffered saline injections would serve
as the control in these experiments.
Measurement of anti-tumor efficacy
The anti-tumor efficacy in the full-scale study was measured by monitoring the tumor
volume after treatment and by histological examination of the tumor tissues. Figure IV-3 showed
the results for HT-1080 bearing mice. Three weekly i.p. injections of free methotrexate at
50mg/kg caused only a slight reduction in tumor size. The difference in the tumor size was not
significant (p=0.194, two-tailed t-test) compared to the control group treated with phosphate-
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buffered saline. A week after the third injection, the study was terminated because the tumor size
in the control group exceeded 10% of the mouse body weight and the mice needed to euthanized
per the guidelines of the animal care committee at our institute. At this point, the tumor size of
the group treated with MTX-PVGLIG-dextran at an equivalent dosage (3 x 50mg of
methotrexate eq./kg of body weight) averaged only 16.8 ±3.6 % of that of the control group. The
inhibition on tumor growth was statistically significant (p= 1.86x 1 0 4, one-tailed t-test). The
study with MTX-GIVGPL-dextran was terminated prematurely, after the first injection on day 6,
because of severe toxicity. Nevertheless, this conjugate was effective in suppressing the tumor
growth with tumor size averaging 37.5 ±9.0 % of that of the control group on day 6 (p=0.00056,
two-tailed t-test).
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Figure IV-3. Tumor progression in HT-1080 bearing mice with different treatments: free
methotrexate (), MTX-PVGLIG-Dextran (A), MTX-GIVGPL-Dextran () and phosphate
buffered saline control (x).Equivalent dosage of methotrexate at 50 mg/kg of mouse body weight
was used at each i.p. injection.
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The HT-1080 fibrosarcoma in the control and free methotrexate groups consisted of
hypercellular sheets of a monomorphic population of oval to spindle shaped cells with coarse
chromatin, prominent nucleoli and a moderate amount of eosinophilic cytoplasm. There were
numerous mitotic figures (Figure IV-4a, b). In contrast, the tumor in the group treated with
MTX-PVGLIG-dextran was much less cellular, had fewer mitotic figures and contained an
infiltrate of foamy histiocytes, likely as a response to the treatment (Figure IV-4c).
Figure IV-4. Histological examination of H&E stained tumor sections from HT-1080 bearing
mice. Tumors were harvested a week after the third injection from mice treated with : a) saline
(control); b) free methotrexate ; c) conjugate MTX-PVGLIG-dextran.
The anti-tumor effect from the conjugate MTX-PVGLIG-dextran was also evident by the
measurement of the proliferative index using Ki67 stain, a marker for dividing cells. The tumor
sections in the saline control and free methotrexate treated group had a much higher proliferative
index than the conjugate treated group (Figure IV-5). We also examined the tumor sections
stained with CD34, a marker for blood vessels (Figure IV-6). However, we were not able to draw
a definite conclusion about the effect of different treatments on the blood vessel density. Further
experiments are needed to determine whether the conjugate has any anti-angiogenesis property.
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Figure IV-5. Histological examination of Ki67 stained tumor sections from HT-1080 bearing
mice. Tumors were harvested a week after the third injection from mice treated with : a) saline
(control); b) free methotrexate ; c) conjugate MTX-PVGLIG-dextran. Brown colorations indicate
the presence of proliferative cells.
Figure IV-6. Histological examination of CD34 stained tumor sections from HT-1080 bearing
mice. Tumors were harvested a week after the third injection from mice treated with: a) saline
(control); b) free methotrexate ; c) conjugate MTX-PVGLIG-dextran. Examples of brown
stained blood vessels are pointed by arrows.
The results were similar in the U-87 bearing mice (Figure IV-7), whose tumor cells have
a higher growth rate than HT-1080. The animal study was terminated a week after the second i.p.
injection to avoid excessive tumor burden in the control group. Treatment using free
methotrexate at 50mg/kg did not have any effect on the tumor size. (p=0.48 compared to the
tumor size of the control group using a two-tailed t-test). In contrast, the tumor growth was
significantly inhibited in the MTX-PVGLIG-dextran group, with the tumor size averaging
17.2±3.7% of the size of the control group (p= 1.52x 10 4 , two-tailed t-test). Similar to the case in
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HT-1080, the study with MTX-GIVGPL-dextran was terminated prematurely on day 6, because
of severe toxicity. The conjugate appeared effective in suppressing the tumor growth with tumor
size averaging 28.9 ±5.6 % of that of the control group on day 6 (p=0.0026, two-tailed t-test).
I
0IIIj
0 5 10 15 20
treatment days
(arrow shows day of . p. injection)
Figure IV-7. Tumor progression in U-87 bearing mice with different treatments: free
methotrexate (), MTX-PVGLIG-Dextran (A), MTX-GIVGPL-Dextran (o) and phosphate
buffered saline control (x).Equivalent dosage of methotrexate at 50 mg/kg of mouse body weight
was used at each i.p. injection.
The U-87 glioblastoma in the control and free methotrexate groups consisted of hypercellular
sheets of large pleomorphic tumor cells with marked nuclear atypia, prominent nucleoli, and
abundant eosinophilic cytoplasm. There were numerous mitotic figures. In contrast, the tumors
in the group treated with MTX-PVGLIG-dextran were much less cellular, had fewer mitotic
figures and contained an infiltrate of foamy histiocytes, similar to that observed in the HT-1080
treatment group (Figure IV-8).
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Tumors were harvested a week after the second injection from mice treated with : a) saline
(control); b) free methotrexate ; c) conjugate MTX-PVGLIG-dextran.
As in the case of HT-1080, the anti-tumor effect from the conjugate MTX-PVGLIG-
dextran in the U-87 model was evident by a reduced proliferative index compared to the control
and free methotrexate treated groups (Figure IV-9). There appeared to be some reduction in the
blood vessel density in the conjugate-treated tumor section (Figure IV-10). However, the
difference was not sufficient to let us draw a definite conclusion about the anti-angiogenesis
property of the conjugate. More experiments are needed to address this potential of the
conjugate.
Figure IV-9. Histological examination of Ki67 stained tumor sections from U-87 bearing mice.
Tumors were harvested a week after the second injection from mice treated with : a) saline
(control); b) free methotrexate ; c) conjugate MTX-PVGLIG-dextran. Brown colorations indicate
the presence of proliferative cells.
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Figure IV-10. Histological examination of CD34 stained tumor sections from U-87 bearing
mice. Tumors were harvested a week after the second injection from mice treated with : a) saline
(control); b) free methotrexate ; c) conjugate MTX-PVGLIG-dextran. Examples of brown
stained blood vessels are pointed by arrows.
In RT-1 12 bearing mice, neither methotrexate nor the conjugate MTX-PVGLIG-dextran
had any significant effect in suppressing tumor growth, as shown in Figure IV-11. The two-tailed
t-tests between the treatment groups and the control groups gave p= 0.48 and 0.30 respectively.
RT-112 tumor grew much slower than HT-1080 and U-87. At one week after the 3 rd injection,
the tumor size of the control group averaged 541±161 cm 3 in RT-1 12 bearing mice whereas the
tumor size averaged 2569±427 cm 3 in the control group of HT-1080 bearing mice. Treatment
with MTX-GIVGPL-dextran did not result in a significant anti-tumor effect (p=0.079, two-tailed
t-test compared with the control) but severe toxicity was again observed after the Ist injection.
The study with this MMP-insensitive conjugate was aborted on day 6 for the same reasons as
aforementioned studies.
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Figure IV-ll1. Tumor progression in RT-112 bearing mice witht different treatments: free
methotrexate (), MTX-PVGLIG-Dextran (A), MTX-GIVGPL-Dextran () and phosphate
buffered saline control (x).Equivalent dosage of methotrexate at 50 mg/kg of mouse body weight
was used at each i.p. injection.
The RT-112 bladder tumor in all treatment groups consisted of an epithelial tumor with
predominantly transitional features, but with focal glandular formation. There was no significant
difference between the control group and the various treatment groups from the standpoint of the
histological evaluation (Figure IV-12).
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Figure IV-12. Histological examination of H&E stained tumor sections from RT-112 bearing
mice. Tumors were harvested a week after the third injection from mice treated with : a) saline
(control); b) free methotrexate ; c) conjugate MTX-PVGLIG-dextran.
Examination of Ki67 staining consistently showed that the proliferative index was similar among
the control, the free methotrexate-treated and the conjugate-treated groups (Figure IV-13).
Compared to HT-1080 and U-87, the control tumor of RT-112 had a lower proliferative index
(Figure IV-5a, Figure IV-9a, Figure IV-13a). CD34 staining was obscured by the cross-staining
on tumor cells (Figure IV-14). As in the previous mouse models, we could not draw a conclusion
about the anti-angiogenesis property of the conjugate based on the histological examination.
Figure IV-13. Histological examination of Ki67 stained tumor sections from RT-112 bearing
mice. Tumors were harvested a week after the third injection from mice treated with : a) saline
(control); b) free methotrexate ; c) conjugate MTX-PVGLIG-dextran. Brown colorations indicate
the presence of proliferative cells.
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Figure IV-14. Histological examination of CD34 stained tumor sections from RT-112 bearing
mice. Tumors were harvested a week after the third injection from mice treated with : a) saline
(control); b) free methotrexate ; c) conjugate MTX-PVGLIG-dextran. Examples of brown
stained blood vessels are pointed by arrows.
Study on systemic side effects
The body weight of the mice was monitored as an indicator of systemic toxicity. To
ensure that the modified dextran carrier of the conjugates did not induce toxicity, mice were
injected with carboxymethyl dextran that was charge neutralized with ethanolamine during the
pilot study (data not shown). A week after three injections, the body weight increased slightly by
7.8% ±4.8%. The lack of any toxic response supported that the modified dextran was
biocompatible. One week after multiple injections with the MMP-sensitive conjugate MTX-
PVGLIG-dextran, we observed a small decrease in body weight in the HT-1080 (-11±1.8%) and
U-87 (-1.3±1.6%) bearing mice. In RT-112 bearing mice, the body weight increased at the end of
the study (+8.6±2.5%). These weight changes were not significantly different from the groups
receiving phosphate buffered saline as a control or with free methotrexate injections. The most
drastic weight loss was observed in the groups treated with MTX-GIVGPL-dextran, the
conjugates with the scrambled peptide linkers insensitive to MMP. In all three tumor models, the
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mice receiving only single injection of MTX-GIVGPL-dextran suffered 15--25% weight loss
(Table IV-4). The mice were severely hypoactive and their hair was ruffled, significantly worse
than the control or the free methotrexate group. As a result, they were sacrificed on day 6 post
treatment because of the drug-related toxicity.
Table IV-4. Summary of side effects due to treatment with free methotrexate, MTX-PVGLIG-
dextran MTX-GIVGPI ,-dextran and saline (controbl
' The body weight at the last day of the study- a week after the last injection-
weight on the treatment start date.
b,c,d Abbreviations for the three tumor models: H=HT-1080; U=U-87; R=RT-112
e Bone marrow tissues were not sampled from U-87 bearing mice
was compared with the initial body
%Body weight Drug-related toxic Drug-related toxic
change a  response in small response in bone
intestine marrow
Phosphate- Hb  -4.5% (+ 2.6%) None None
buffered saline Uc -1.5% (+ 3.0%) None e
(Control) RF +10% (+ 3.7%) None None
Free methotrexate H -16% (+ 2.3%) None-to-minimal None
U +4.0%(± 2.8%) None-to-minimal
R +10% (+ 3.7%) None None
Conjugate MTX- H -11% (± 1.8%) None-to-minimal None
PVGLIG-dextran U -1.3% (+ 1.6%) None-to-minimal e
R +8.6%(+ 2.5%) None None
Conjugate MTX- H -18% (+ 3.0%) Moderate Moderate-to-severe
GIVGPL-dextran U -23% (± 1.9%) Moderate
R -21%(± 1.6%) Moderate Moderate-to-severe
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The side effects were further evaluated by histological examinations of the major tissues,
including small intestine, bone marrow, liver, kidney, spleen and skin. Regardless of the type of
tumor model, there was moderate-to-severe toxicity in the small intestines and the bone marrows
in all of the mice treated with the MMP-insensitive conjugate MTX-GIVGPL-dextran (Table
IV-4). The drastic weight loss and these tissue damages showed that MTX-GIVGPL-dextran
caused toxicity, independent of the MMP expression level of the tumor model.
The histologic changes in the small intestine of MTX-GIVGPL-dextran treated mice
consisted of epithelial necrosis with focal regenerative changes, and occasional degeneration of
the muscularis without evidence of frank perforation. There were only a limited number of cases
with minimal small intestinal toxicity in the mice treated with the MTX-PVGLIG-dextran or
with free methotrexate, consisting of regenerative changes in the epithelium and increased
chronic inflammation in the lamina propria. In most cases, the small intestines appeared healthy
and similar to the control mice treated with saline (Figure IV-15 and Appendix A).
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Figure IV-15. Histological examination of the small intestine sections from HT-1080 bearing
mice. Tissues were harvested from mice treated with: a) 3 injections of saline (control); b) 3
injections of free methotrexate ; c) 3 injections of conjugate MTX-PVGLIG-dextran; d) 1
injection of conjugate MTX-GIVGPL-dextran.
In the bone marrow, there was necrosis and hemorrhage with a loss of all hematopoetic
lineages in the MTX-GIVGPL-dextran treated mice. These signs of tissue damage were absent in
the mice treated with saline, free methotrexate or MTX-PVGLIG-dextran (Figure IV-16 and
Appendix B).
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Figure IV-16. Histological examination of the bone marrow sections from HT-1080 bearing
mice. Tissues were harvested from mice treated with : a) 3 injections of saline (control); b) 3-
injections of free methotrexate ; c) 3 injections of conjugate MTX-PVGLIG-dextran; d) 1
injection of conjugate MTX-GIVGPL-dextran.
Liver (Appendix C), kidney (Appendix D), spleen (Appendix E) and skin (Appendix F) appeared
healthy in all, treatment groups. There was occasional non-specific mild extramedullary
hematopoiesis in the liver and spleen.
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Discussion
The primary goal in this study was to evaluate the anti-tumor efficacy of the new dextran-
peptide-methotrexate conjugate in an in vivo model system. Based on the pilot experiments, the
dose of 50mg methotrexate eq./kg of body weight administrated weekly up to three times was
selected. This dosage equals half the maximum tolerated dose found by Burger using free
methotrexate in mice 13. At this dosage, we did not detect any therapeutic effect for free
methotrexate using our animal models. On the other hand, the MTX-PVGLIG-dextran conjugate
demonstrated an increased anti-tumor efficacy without any significant side effect in HT-1080
and U-87 bearing mice. The inhibition in tumor growth (by 83% in both models) was on par with
the best results found in the literature on the polymer-drug conjugate investigation (Table IV-1).
Since the potency of the released MTX-peptide analog was two orders of magnitude lower than
free methotrexate, this promising result suggested that the conjugate had a significantly higher
tumor targeting ratio.
The superior anti-tumor efficacy could possibly be due to the prolonged circulation of
methotrexate as a result of passive targeting. In its free form, methotrexate is cleared rapidly
from the body by the kidney14 . The dextran carrier we selected for conjugation with the drug has
a nominal molecular weight of 70,000 Da. Reports from Kopecek's group and others have shown
that the renal excretion limit is about 40,000 Da' 5. Our conjugate is intentionally sized above this
threshold. The tumor targeting ratio could also be potentially enhanced by the mediation of
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MMPs. These tumor-associated enzymes could release more active peptide-methotrexate from
the conjugate at the tumor tissue.
We attempted to shed some light on the targeting mechanism by comparing the in vivo
observations among tumor models with different levels of MMP expression. Out of the three
tumor models, only RT-112 did not show any treatment effect by the MTX-PVGLIG-dextran
conjugate. It was also the cell line with the lowest level of MMP expression. As an anti-
metabolite, methotrexate must be released from the carrier to exert its effect on cell growth by
inhibiting DNA synthesis. The release can happen in two ways: 1) by non-specific endocytosis,
as conjugates are internalized by cells and methotrexate can be released by either acid hydrolysis
or lysosomal enzyme digestion or 2) by MMP cleavage of the peptide linker in the extracellular
vicinity of tumor tissue. The latter route of localized drug release from MTX-PVGLIG-dextran is
not as probable in RT-112 as in HT-1080 or U-87, due to their differential MMP expression
levels. However, RT-112 also differs from HT-1080 and U-87 in its in vivo growth kinetics, so
the lack of treatment effect may not be solely due to the low expression of MMP-2 and MMP-9
in RT-112. The treatment effectiveness of the conjugate was accompanied by a reduction in
proliferative index. This is in agreement with the pharmacological action of methotrexate, which
hinders proliferation by inhibiting DNA synthesis through its binding of dihydrofolate reductase.
As the mechanism to suppress tumor growth is related to the inhibition of tumor cell
proliferation'4 , if the tumor model is not highly proliferative, as in the case of RT-112, the
therapeutic effect of free methotrexate or the conjugate will be limited.
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The new conjugate, MTX-PVGLIG-dextran, was well tolerated by the mice under the
current treatment regime. The weight drop was minor, and histological examination of the major
organs and tissues did not find any significant toxicity. In clinical uses, free methotrexate is
known to cause side effects in the gastrointestinal tract and in the bone marrow14 . In our study,
the mice treated by free methotrexate at the designated dosage did not show any severe drug-
related toxicity. However, some HT-1080 and RT-112 bearing mice died from unknown reasons
prior the completion of the free methotrexate treatment. These accounted for approximately 13%
of the total number in the methotrexate group and we did not observe any similar case in the
saline control group.
The severe and acute drug-related toxicity caused by the MMP-insensitive conjugate,
MTX-GIVGPL-dextran, was surprising. This conjugate resulted in more than 20% weight drop
causing us to sacrifice the mice after only the first injection. Severe necrosis within the small
bowel and bone marrow was present. This form differs from the well-tolerated MTX-PVGLIG-
dextran only in the sequence of amino acids in the peptide linker. Without an MMP-sensitive
linker, MTX-GIVGPL-dextran was predicted to have a lower anti-tumor efficacy because of its
inability to release active peptide-methotrexate. However, it seemed capable of inhibiting tumor
growth, despite the fact that the study ended prematurely due to drug-related toxicity.
Differences between the two types of the conjugates in systemic side effects suggest that MMP-
independent release from MTX-GIVGPL-dextran is possible.
From our in vivo study, it was evident that MTX-PVGLIG-dextran is a promising vehicle
to achieve tumor-targeted delivery of methotrexate in MMP-overexpressing models. However, it
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was unclear if and how the difference in drug-related toxicity was related to the MMP specificity
of the linkers. Further studies in assessing the biodistribution of the conjugate and the drug
release profile should be useful in understanding the targeting mechanism of the new conjugate.
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CHAPTER V: BIODISTRIBUTION STUDY WITH NEW DEXTRAN-
PEPTIDE-METHOTREXATE CONJUGATES
Introduction
As described in Chapter IV, we observed that the new conjugate with a MMP-
sensitive linker, MTX-PVGLIG-dextran, demonstrated a superior anti-tumor effect
compared to free drug (methotrexate). In our working hypothesis, the improved efficacy
is a result of the passive and active targeting capabilities of the new conjugate. Unlike
the MMP-sensitive conjugate, we found that the MMP-insensitive conjugate caused
severe side effects. The targeting mechanism of the new conjugate and the cause of side
effects are the topics of investigation in this chapter.
In passive targeting, the drug molecules can circulate in the blood plasma for a
prolonged period of time as a result of their conjugation to a polymer backbone,
presumably due to reduced clearance by the kidney and the liver. The plasma drug
concentration is maintained above the therapeutic concentration longer and the conjugate
is allowed additional time to reach the targeted tissues. Maeda has discovered the effect
called enhanced permeation and retention (EPR), which describes the preferential
accumulation of large macromolecules in the tumor tissues. Because of the
pathophysiology of tumor tissues, which includes leaky blood vessels and poor lymphatic
drainage, high molecular weight conjugates can theoretically permeate better into the
solid tumor and remain at the tumor site .
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Traditionally, the design criteria of the linker between the drug and the polymer
are: 1) the linker is stable during storage and remains intact in the general circulation; and
2) it is able to be cleaved to release the drug after the conjugate is internalized into the
cell. The latter requirement has prompted the development of acid-labile linkers
cleavable by low pH and peptide linkers cleavable by ubiquitous intracellular enzymes
such as lysosomal enzymes2. The function of actively targeting the delivery to the
diseased tissues has been carried out by homing signals such as monoclonal antibodies
and antigens for specific receptors 3 4 5 6. We have proposed a linker that is sensitive to
disease-associated enzymes. These enzymes are characteristic of the immediate
extracellular environment of the target tissue. In the context of tumor targeting, a linker
labile to tumor-associated enzymes can potentially provide a means for site-specific drug
delivery. For our conjugate, the linker joining methotrexate to the dextran backbone has
been optimized for cleavage by matrix-metalloproteinases7' 9. These enzymes are
overexpressed in a number of cancers0' 11 12 13 14 15 and are implicated with various
functions for the growth and metastasis of tumor cells6 .
We intended to verify and measure the extent of passive and active targeting by
assessing the plasma pharmacokinetics and tissue distribution in mice with MMP-
overexpressing tumor xenografts. To address our questions regarding passive targeting
and EPR effect, we compared the conjugates with free drug. To gauge the effects of
MMPs in mediating drug release from our conjugates, we compared the MMP-sensitive
conjugate (MTX-PVGLIG-dextran) with the MMP-insensitive conjugate (MTX-
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GIVGPL-dextran). We attempted to find supporting evidence for our hypothesis that
enzymes other than MMPs are involved in causing the discrepancy in drug-related
toxicity between the two types of conjugates.
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Materials and Methods
Methotrexate was ordered from Sigma. The two conjugates, MTX-PVGLIG-
dextran and MTX-GIVGPL-dextran were prepared as described9 .
Human xenograft tumor models in mice were established as described'7 , and were
in accordance to the guidelines of the Animal Care Committee at the Massachusetts
Institute of Technology. HT-1080 bearing mice with tumor size of 500-1500mm3 were
injected i.p. with either methotrexate, MTX-PVGLIG-dextran or MTX-GIVGPL-dextran
at 50mg MTX eq./kg mouse body weight. One group of mice receiving MTX-PVGLIG-
dextran was also injected with minocyclin at 50mg/kg twice daily starting from the day
before the conjugate injection. Blood and major tissues were harvested from at least three
mice were used for each specified time point.
Tissue homogenate was obtained by homogenizing the thawed tissue in a cold
buffer (0.5M sucrose, 20mM Tris, 5.5mM EDTA with complete protease inhibitor
(Roche Cat. No. 1873580) and pH adjusted to 7.5) at 25% w/w and centrifuging at
16000g at 8C for 10 minutes. The supematant was retained. Tissue homogenate and
plasma samples from mice injected with the two conjugates were further processed with a
membrane device to separate the uncleaved conjugate from the released methotrexate-
peptide.
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Blood plasma was diluted 10-fold and heart homogenate was diluted 5-fold with a
buffer (same composition as the homogenization buffer) at room temperature. The diluted
sample was centrifuged in a Microcon with 10,000 MWCO (Millipore) at 14000g for 30
minutes at room temperature. This step was repeated 3 times and the retentate chamber
was replenished with the buffer after each spin. Filtrate from the first two spins,
containing methotrexate-peptide, which was smaller than the cutoff of the membrane,
was pooled for measurement. Retentate obtained after the last spin contained the
uncleaved conjugate and was also measured for the methotrexate equivalent
concentration.
Other types of tissue homogenate were first precipitated by adding an equal
volume of acetonitrile and centrifuging at 13000rpm for 10 min at room temperature. The
supernatant was processed with a membrane ultrafiltration device, Ultrafree-MC with
10,000 MWCO (Millipore), by spinning 2 times at 5600g for 60 minutes at room
temperature. A solution of 1:1 acetonitrile: homogenization buffer was used to replenish
the retentate chamber after each spin. Filtrate from the first spin and the retentate after the
last spin was measured for the methotrexate equivalent concentrations.
The concentrations of methotrexate, methotrexate-peptide and dextran-peptide-
methotrexate conjugate were measured by the TDxFLx® system using the reagents for
methotrexate quantitation (Abbott Laboratory). The instrument made use of a technology
combining fluorescence polarization and competitive binding immunoassay 18. To obtain
the concentration of methotrexate-peptide and dextran-peptide-methotrexate, we
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multiplied the TDx readouts by 1.8 and 2.0 respectively. These conversion factors were
obtained by a linear regression between the TDx readouts and the known concentrations
of these two types of samples. The formulae used to calculate values found in the current
report were listed below.
% conjugate = Percentage of equivalent methotrexate found in uncleaved conjugate
= concentration of conjugate / (concentration of methotrexate-peptide + concentration of
conjugate) x 100%
Total methotrexate equivalent concentration in tissue (from mice injected with free
methotrexate) = homogenate reading x 4
Total methotrexate equivalent concentration in plasma (from mice injected with free
methotrexate) = plasma reading
Total methotrexate equivalent concentration in tissue (from mice injected with conjugate)
= homogenate reading x 4 x (% conjugate x 2.0 + (1.0-% conjugate) x 1.8)
Total methotrexate equivalent concentration in plasma (from mice injected with
conjugate) = homogenate reading x (% conjugate x 2.0 + (1.0-% conjugate) x 1.8)
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The half-life of elimination of the two conjugates in plasma was estimated by
assuming a one-compartment model with first-order absorption and first-order
elimination (Figure V-1).
Central
Dose Absorotion Elimination
ka Comaprtment K
i n.
Figure V-1. Classic one-compartmental model for the evaluation of plasma
pharmacokinetics of the polymer-peptide-drug conjugates
The integrated equation of this model is:
C = Dka (e-K -kat)Vd(k -K)e
Where C represents the drug concentration in plasma, D represents the total
dosage, Vd represents the volume of distribution, k, equals the absorption rate constant
and K equals the elimination rate constant. In the usual case when ka > K, the second
exponential term becomes negligible at large time t. K can be obtained from the linear
regression of the terminal linear portion of the semi-log graph plotting drug concentration
versus time. The half-life of circulation for the two conjugates was calculated by t,,2
= 0.693 / K. The area-under-curve (AUC) was calculated using the trapezoidal rule.
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Results
To explain the observations we made regarding the anti-tumor efficacy and the
systemic toxicity, we measured the biodistribution of three different types of dosage
forms in HT-1080 bearing mice: free methotrexate, the MMP-sensitive conjugate, and the
MMP-insensitive conjugate. HT-1080 is a fibrosacroma known to overexpress MMP-2
and MMP-9 and we confirmed its expression levels in a previous experiment (Chapter
IV). Our detection method allowed us to distinguish between the uncleaved conjugate
and the cleavage product in blood plasma and tissue homogenate.
Figure V-2 presents the plasma pharmacokinetics of the free methotrexate and the
two conjugates. By two hours after free methotrexate injection, most of the dose was
cleared from the body. The area-under-curve (AUC) for free methotrexate was 64 AM-h
and was significantly lower than either conjugate: 2.24 x 10 4 M-h for MTX-PVGLIG-
dextran and 1.90 x 104 gM-h for MTX-GIVGPL-dextran. The concentration-time curves
for the two conjugates with different peptide linkers were similar. The maximum plasma
concentration occurred at approximately 5 hours post i.p. injection. The plateau at the
maximum lasted to about 24 hours post injection. The regression on the data in the
terminal portion yielded C, (pM) = 470.18e-0°°21(hr) for MTX-PVGLIG-dextran and
C (M) = 517.74e-°0.023 hr) for MTX-GIVGPL-dextran. Thus the half life of elimination
was 32.5 hours for the former and 30.3 hours for the later conjugate. For both conjugates,
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the dosage forms remained intact in the circulation. More than 99% of the methotrexate
equivalent was found in the uncleaved conjugate form up to at least 72 hours post
injection.
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Figure V-2. Plasma pharmacokinetics of methotrexate, conjugate MTX-PVGLIG-dextran
and conjugate MTX-GIVGPL-dextran. Shown in this figure is the concentration of
methotrexate equivalent in mice injected with free methotrexate (), MTX-PVGLIG-
dextran () and MTX-GIVGPL-dextran (A). The percentage of methotrexate found in
uncleaved conjugate is plotted for MTX-PVGLIG-dextran (o) and MTX-GIVGPL-
dextran(A).
The tissue distribution of the free methotrexate and the two conjugates at 5 and 24
hours post injection are compared in Figure V-3, Figure V-4 and Figure V-5. The
concentrations in the tissues reflected the concentrations in the plasma. Not surprisingly,
the drug concentrations within the tumor tissues and the major organs, including heart,
liver, kidney, lung, small intestines, were much lower for the free methotrexate than for
the two conjugates. The tissue distributions for the conjugates differing in peptide linkers
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were similar. For both types of conjugates, the total methotrexate eq. at the tumor tissue
was significantly higher than the free drug. The accumulation differed by two orders of
magnitude at 5h and 24h post injection.
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Figure V-3. Tissue distribution of methotrexate in mice receiving free methotrexate, at 5
hours (::and 24 hours (.) post injection.
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Figure V-4. Tissue distribution of methotrexate equivalent in mice receiving MTX-
PVGLIG-dextran, at 5 hours (:) and 24 hours (m) post injection.
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Figure V-5. Tissue distribution of methotrexate equivalent in mice receiving MTX-
GIVGPL-dextran, at 5 hours ()::::: and 24 hours (m) post injection.
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Figure V-6. Comparison of tumor accumulation in mice receiving the two different
conjugates, at 5 hours (iii) and 24 hours () post injection. One group tested with MMP-
sensitive conjugate MTX-PVGLIG-dextran also received injection of minocyclin, an
MMP inhibitor.
Slightly more accumulation in the tumor was found with MTX-PVGLIG-dextran
than with MTX-GIVGPL-dextran (Figure V-6). The difference was 1.8 fold at 5h
(p=0.12) and 1.5 fold at 24h (p=0.075). This difference disappeared when the mice
receiving MTX-PVGLIG-dextran injections were also treated with minocyclin, a broad
inhibitor on MMP. This suggested that the higher tumor accumulation of the MMP-
sensitive conjugate compared to the MMP-insensitive conjugate was a result of the
enzymatic release from MMP.
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Although the MTX-PVGLIG-dextran is highly sensitive in releasing peptide-
MTX in the presence of MMP-2 and MMP-9 in vitro9, we noted that more than half of
the MMP-sensitive conjugate in the tumor tissue remained in an uncleaved form up to 48
hours after injection (Figure V-7).
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Figure V-7. Proportion of conjugate MTX-PVGLIG-dextran remaining uncleaved in the
tumor tissues of HT-1080 bearing mice.
Nevertheless, the amount of peptidyl methotrexate released by the conjugate
MTX-PVGLIG-dextran was sufficient to inhibit tumor growth in vivo (Chapter IV). We
found that from 5 to 48 hours post injection, the concentration of the peptidyl
methotrexate released from this conjugate remained at or above 10IM (Figure V-8), the
IC50 concentration of MTX-PVG in a HT-1080 cell culture assay (Chapter III). At the
current dosage of 50mg MTX eq./kg, the conjugate is able to attain a therapeutic
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concentration during this time frame. The allows methotrexate to exert its
pharmacological action to reduce the proliferative index of the tumor cells .
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Figure V-8. Concentration of peptidyl methotrexate released from the conjugate MTX-
PVGLIG-dextran post injection in HT-1080 bearing mice.
Besides answering questions about the targeting mechanism to achieve anti-tumor
efficacy, the biodistribution study is instructive in explaining the side effects described in
Chapter IV. Clinically, methotrexate is known to cause side effects in the gastrointestinal
tract. Although we only observed mild damage to the small intestine in the free
methotrexate treated mice, the small intestine was the major site of accumulation of the
free drug (Figure V-3). The amount of drug peaked at this tissue rapidly after injection,
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at around 0.5 hour (Figure V-9a). The drug concentration in the small intestine, the
major site of side effects, was compared with the drug concentration in the tumor, the
target site of the chemotherapy (Figure V-9). For the free methotrexate, the ratio of AUC
of small intestine to tumor = 4.3. This ratio was significantly higher than the
corresponding value for the two conjugates. (1.23 for MTX-PVGLIG-dextran and 1.65
for MTX-GIVGPL-dextran). As shown in Chapter IV, free methotrexate at this dosage
did not have any significant anti-tumor effect. One might expect that if the dosage were
to increase to a therapeutic level, severe toxicity would be expected in the small intestine
due to the skewed distribution present in this tissue.
In the small intestines, the two conjugates were comparable in their total
methotrexate equivalent accumulations and their concentration-time profiles. The tissue
concentration peaked at 5 hours post injections and remained at the maximum plateau
until 24 hours before it slowly declined (Figure V-9b,c). However, the proportion of
conjugate remaining uncleaved was dependent on the sequence of the peptide linker of
the conjugate (Table V-l). A higher percentage of the conjugates with the PVGLIG
linkers were cleaved. MMPs are not known to be present in the bowel and the injection of
minocyclin did not change our experimental observation. These led us to hypothesize that
the discrepancy in drug-related toxicity resulting from the two conjugates was due to
their different susceptibility to enzymes other than MMP. Note that the assay
differentiated uncleaved conjugate and released drug based on size separation, so the
exact form of the released drug was not known. The possible entities included
methotrexate-peptide analogs of varying number of amino acids and free methotrexate.
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Figure V-9. Comparison of the total methotrexate concentration in the small intestine (i)
and the tumor tissue (0) in HT-1080 bearing mice injected with a) free methotrexate, b)
MTX-PVGLIG-dextran and c) MTX-GIVGPL-dextran.
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Table V-1. Comparison of accumulation of total methotrexate equivalent and the
percentage in uncleaved conjugate form in the small intestine at 5h and 24h post injection
Injection MTX eq.in small percentage of MTX
intestine (pM) in uncleaved
conjugate
MTX-PVGLIG-dextran 99±67 0.80±0.91
MTX-GIVGPL-dextran 111±26 28±22
MTX-PVGLIG-dextran + 173±37 1.1±1.7
minocyclin
MTX-PVGLIG-dextran 81±28 1.4±1.4
MTX-GIVGPL-dextran 108±66 8.9±6.9
Ec MTX-PVGLIG-dextran + 118±47 0.31±0.32
minocyclin
As we reported previously, the cytotoxicity of methotrexate was decreased by two
orders of magnitude when the free drug was covalently linked to Pro-Val-Gly (Chapter
III)9. MTX-PVG was the product released from the conjugate MTX-PVGLIG-dextran in
the presence of MMP-2 or MMP-9. When we compared the cytotoxicity of MTX-peptide
with varying number of amino acids: MTX-G, MTX-GI and MTX-GIV (Figure V-10),
we found that the reduction in the potency of the free methotrexate increased with the
number of amino acids attached to the free methotrexate.
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Figure V-10. Cytotoxicity of methotrexate and different types of methotrexate-peptide
analogs: MTX (A), MTX-G (o), MTX-GI (o), MTX-GIV (A) and MTX-PVG (). The
test was performed in HT-1080 cell culture.
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Discussion
This biodistribution study was carried out to examine the targeting mechanism of
the new dextran-peptide-methotrexate conjugate. By comparing the plasma
pharmacokinetics of free methotrexate to the MMP-sensitive conjugate, MTX-PVGLIG-
dextran, and MMP-insensitive conjugate, MTX-GIVGPL-dextran (Figure V-2), we
confirmed that the conjugates demonstrated passive targeting. While methotrexate is
mainly cleared from the body through the urine 19, the high molecular weight dextran
carrier we selected for conjugation was able to reduce renal excretion and increase
circulation time. Independent of the peptide linker sequence, the conjugates remained
uncleaved in the blood stream for a prolonged period of time. Even when the peptide
linker is labile to MMPs and possibly other endopeptidases in the bloodstream, the
presence of some serum proteins, such as a-macroglobulin, may act as inhibitors to these
enzymes 20. The peptide linker is flanked on the terminals by methotrexate and dextran.
These moieties should also protect the peptide from the attack of exopeptidases. This
explained the observation that the drugs remained attached to the dextran carrier for at
least 3 days in the plasma, enabling a prolonged circulation time and increased tissue
accumulation.
The higher plasma concentration of MTX eq. resulted in higher concentrations in
the tissues and contributed to the increase in the tumor targeting ratio --- the amount of
drug localized to the tumor site normalized by the dosage (Figure V-3, Figure V-4 and
Figure V-5). Despite the difference in the peptide linkers, the features designed for
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passive targeting, including size and hydrophilicity, are the same for both conjugates.
These features also help to achieve tumor targeting by the EPR effect. In comparing the
ratio of AUC of the tumor to the small intestine, we observed a favorable shift towards
the tumor for both conjugates (Figure V-9). The enhancement of tumor targeting ratio of
both conjugates relative to the free drug illustrates the advantages of passive targeting
and EPR effects.
As shown in Figure V-6, MTX-PVGLIG-dextran, the MMP-sensitive conjugate,
surpassed MTX-GIVGPL-dextran, the MMP-insensitive conjugate, in the drug
accumulation in the tumor tissue without statistical significance. The new conjugate
therefore achieved selective delivery to the tumor tissue mainly by passive targeting and
the EPR effects, and MMP-mediated release was not the primary targeting mechanism.
Although the conjugate MTX-PVGLIG-dextran is highly sensitive to MMP-2 and MMP-
9 in releasing MTX-PVG in vitro (Chapter III) 9, tumor-specific delivery of peptidyl
methotrexate mediated by MMP was not significant in vivo. We can think of two possible
explanations. First, we consider the competition of non-specific drug uptake. At the
tumor tissue, drug uptake can happen through two processes. Regardless of the linker
specificity, conjugates can be internalized by the tumor cells via non-specific
endocytosis. For the conjugates with MMP-sensitive linkers, enzyme-mediated release of
the peptidyl methotrexate provides a different venue for site-specific delivery. The
relative importance of these two processes depends on their relative rates. The enzymatic
release rate by MMP can be modeled by the Michaelis Menten mechanism. The rate
plateaus tokca, * Eo as the conjugate concentration increases. (kcat is the turnover rate
155
from substrate-enzyme complex to product and E0 is the enzyme concentration of MMP.)
Fluid-phased endocytotic uptake can be modeled as a first-order process and its rate thus
increases linearly with the conjugate concentration. At low conjugate concentration, the
rate of MMP-mediated release is higher and therefore has a more prominent role. At high
conjugate concentration, the reverse is true. In our animal study, a high dosage (50mg
MTX eq./kg) is administrated because MTX-PVG has reduced potency compared to free
methotrexate9. This high dosage may have caused the endocytotic uptake to dominate
over the MMP-mediated release.
Second, we consider the heterogeneity and complexity of the tumor environment
in vivo. The activity of MMPs is regulated by host inhibitors such as TIMPs 20 and the
spatial distribution of MMPs within the tumor tissue may not be even. Our conjugate,
because of the large size, may not be able to penetrate the tumor tissue evenly2'.
Together, these can cause the conjugate MTX-PVGLIG-dextran to demonstrate a lower
sensitivity in the mouse model. As a supporting consideration, we observed that most of
the methotrexate remained attached to the dextran carrier in the tumor tissue for at least
two days after the injection (Figure V-7).
Although the amount of total methotrexate eq. in the small intestine between the
two types of conjugates was similar, we found that the percentage cleavage was
significantly different (Table V-1). Furthermore, the potency of the release product from
the conjugate varied significantly based on the number of amino acids attached (Figure
V-10). These results confirm our earlier suspicion that enzymes other than MMPs in the
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normal tissues (such as the small intestine) are involved. The significant difference in the
side effects found in the bowel could have resulted in the release of more potent toxic
products (methotrexate-peptide with shorter peptide) from one conjugate but not the
other. There are many endopeptidases and exopeptidases that are present in the small
intestine22 which can potentially cleave the conjugate MTX-GIVGPL-dextran to release
the active component. Enzymes such as elastase, carboxypeptidase and aminopeptidase
are possibly involved but we are unable to pinpoint the key enzyme with our current
method.
157
References
1. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in
cancer chemotherapy. Advanced Drug Delivery Reviews 2001 ;46(1-3): 169-85.
2. Putnam D, Kopecek J. Polymer conjugates with anticancer activity Biopolymers II,
vol. 122, 1995:55-123.
3. Li C. Poly(L-glutamic acid) - anticancer drug conjugates. Advanced Drug Delivery
Reviews 2002;54(5):695-713.
4. Lu ZR, Kopeckova P, Kopecek J. Polymerizable Fab' antibody fragments for targeting
of anticancer drugs. Nature Biotechnology 1999; 17(11 ): 1101-04.
5. Flanagan PA, Duncan R, Subr V, Ulbrich K, Kopeckova P, Kopecek J. Evaluation of
Protein-N-(2-Hydroxypropyl)Methacrylamide Copolymer Conjugates as Targetable
Drug-Carriers .2. Body Distribution of Conjugates Containing Transferrin,
Antitransferrin Receptor Antibody or Anti-Thy 1.2 Antibody and Effectiveness of
Transferrin-Containing Daunomycin Conjugates against Mouse L1210 Leukemia Invivo.
Journal of Controlled Release 1992; 18(1):25-37.
6. Lu YJ, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic
agents. Advanced Drug Delivery Reviews 2002;54(5):675-93.
7. Chau Y, Langer RS. Important factors in designing targeted delivery of cancer
therapeutics via MMP-2 mediation. Journal of Controlled Release 2003;91(1-2):239-40.
8. Chau Y, D. P, Dang N, Tan F, Langer R: Investigation of new tumor-targeting
conjugates with MMP sensitive linkers Controlled Release Society Annual Meeting 2004.
158
9. Chau Y, Tan FE, Langer R. Synthesis and characterization of dextran-peptide-
methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II
and matrix metalloproteinase IX. Bioconjugate Chemistry 2004;15(4):931-41.
10. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD,
Balkwill FR. Activity of Type-IV Collagenases in Benign and Malignant Breast Disease.
British Journal of Cancer 1993;67(5):1126-31.
11. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson JB,
Williams JL, Rees RC. Matrix Metalloproteinase-9 Expression in Primary Human
Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia. British Journal of Cancer
1994;69(1): 177-82.
12. Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetlerstevenson
WG. Increased Expression of the Mr 72,000 Type-IV Collagenase in Human Colonic
Adenocarcinoma. Cancer Research 1991 ;51 (1):439-44.
13. Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and Activity of MMPs
and Their Regulators in Ovarian-Cancer. International Journal of Cancer 1994;58(1):50-
56.
14. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D,
Hanby A, Balkwill F. Levels of Matrix Metalloproteases in Bladder-Cancer Correlate
with Tumor Grade and Invasion. Cancer Research 1993;53(22):5365-69.
15. Derrico A, Garbisa S, Liotta LA, Castronovo V, Stetlerstevenson WG, Grigioni WF.
Augmentation of Type-Iv Collagenase, Laminin Receptor, and Ki67 Proliferation
Antigen Associated with Human Colon, Gastric, and Breast-Carcinoma Progression.
Modern Pathology 1991 ;4(2):239-46.
159
16. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer
progression. Nature Reviews Cancer 2002;2(3):161-74.
17. Chau Y, Padera RF, Dang NM, Langer R. Anti-tumor efficacy of a novel polymer-
peptide-drug conjugate in human tumor xenograft models. Submitted to International
Journal of Cancer 2005.
18. Dandliker SB, Kelly RJ, Dandliker J, et.al. Fluorescence polarization immunoassay.
Theory and experimental method. Immunochemistry 1973;10:219-27.
19. Chamber BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. In: Hardman
JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of
Therapeutics: The McGraw-Hill Companies, Inc., 2001:1389.
20. Woessner JF, Nagase H. Matrix Metalloproteinases and TIMPs. New York: Oxford
university press, 2000.
21. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Advanced Drug
Delivery Reviews 2001 ;46(1-3): 149-68.
22. Alpers DH. Digestion and Absorption of Carbohydrates and Proteins. In: Johnson LR,
Christensen J, Jackson MJ, Jacobson ED, Walsh JH, eds. Physiology of the
Gastrointestinal Tract, ed. Second Edition, vol. 2 New York: Raven Press, 1987:1469.
160
Chapter VI: OPPORTUNITIES FOR ENZYMATIC
MEDIATIONS IN BIOMEDICAL APPLICATIONS
Introduction
We have designed a novel polymer-drug conjugate containing linkers cleavable
by disease-associated enzymes. As an example, we synthesized and characterized
dextran-peptide-chemotherapeutic conjugates to improve anticancer treatment by targeted
delivery. The concept of using disease-associated enzymes as mediators to elicit
biologically relevant responses is applicable for designing new drug delivery vehicles in
addition to polymer-drug conjugates, as well as for devising other biomedical
applications. Because of the strong correlation of MMPs with cancer progression, these
enzymes have been studied widely in the past two decades. The work in this dissertation
has joined a number of research groups to pioneer biomedical applications using MMP
activation. In this chapter, the potentials of enzymatic mediations are illustrated by the
examples employing MMP-based activation. In addition to helping us to improve the
design of a drug-delivery vehicle to make better use of an enzyme's activity, these
examples also let us perceive the future opportunites of MMP-mediated applications.
The MMP family consists of at least 25 zinc-dependent endoproteinases, most of
which were discovered in the past decade' (Table VI-1). These matrix-metalloproteinases
together can break down all the major proteins comprising the ECM and the basement
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membrane. The common names of some of these MMPs, such as collagenase and
gelatinase, indicate the natural substrates for these proteases. In the quest of
understanding the roles of these enzymes in tumor progression, a myriad of substrates
other than the ECM, such as growth factors, angiogenic factors and syndecans' 2, were
found for these enzymes. In addition to cancer, these enzymes play major roles in
biological processes wherein tissue remodeling is essential. They are involved in normal
processes such as wound healing and embryo development. In pathological processes,
they are associated with inflammation and unchecked tissue remodeling, and are found
dysregulated in diseases such as cancer, cardiovascular diseases, and arthritis. Because of
the important roles of MMPs in these processes, they can be exploited in various
applications for attaining regulation of biological processes, providing therapy and
obtaining diagnosis.
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Table VI-1. The matrix-metalloproteinase family'
aii •• " •• ...
Collagenase-1, interstitial collagenase,
_, _ .. Stromelysin-1, transin-1, proteoglycanase, I
c;,, 1.. .;, A,,.;. Collagenase-2, neutrophil collagenase, PMN I
MMP-14 Transmembrane MT -MMP, MT-MMP-1
MMP-16 Transmembrane MT3-MMP, MT-MMP-3
Collagenase-4 (Xenopus; no humanMMP-18 Simple hemopexin domain ologue known)homologue known)
MMP-20 Simle hemoexin domain Enamel ysin
MMP-22 Simple hemopexin domain CMMP (chicken, no human homologue
MMP-22 Simple hemopexin domain num
I , Iv IJ-,l " VL I .J-VIIVI 4 IL.VIV A -- VLVII -J
MMP-26 GPI-linked Endometase, matrilysin-2
Furin-activated andMMP-28 secreted Epilysin
secreted
No designation Simple hemopexin domain Mcol-B (Mouse)
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Development of inhibitors against MMPs for cancer therapy
The development of inhibitors against MMPs for cancer therapy was sparked by the
strong correlation between MMPs and tumor progression. Initially, the assumption was
that the primary roles of MMPs were to break down the basement membrane and the
ECM, and hence were important especially in tumor expansion and invasion during the
late stage and during metastasis. More functions of the MMPs have been discovered
suggesting their involvement at an earlier stage and at multiple levels, such as generating
growth signals and releasing angiogenesis factors .
In animal models, the inhibition of MMPs by small molecules or by gene knockout
results in significant anti-tumor efficacy. The chemical inhibitors of MMPs were quickly
tested in clinical trials in the early 1990s, when only 3 MMPs were found and much less
was known about these enzymes. The disappointing results of these clinical trials and the
lessons learnt from the early developments are found in a number of good reviews3 -5. In
hindsight, one can attribute three causes for the results of the clinical trials: 1) the failure
to recognize that MMP inhibitors can moderate the diseases in multiple stages and that
treatment at an early stage can potentially confer more benefits than at a late stage; 2) the
failure to recognize that inhibitors have cross reactivity against enzymes essential for
normal functions and thus induce side effects ( for example, mucoskeletal inflammation
is caused by the unintentional inhibition of ADAMs- a disintegrin and
metalloproteinases); 3) the lack of a detection method for establishing the effectiveness
of the treatment and thereby the lack of appropriate measures to determine the optimal
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dosages. Despite these initial disappointments, the lessons learnt should give a good
direction to the future development of MMP inhibitors. Furthermore, because of the
immense interest to develop synthetic inhibitors against MMPs, the substrate specificity
of these enzymes has been studied extensively. This knowledge is applicable for
developing MMP-mediated applications.
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Drug delivery vehicles with MMP-cleavable linkers
MMP inhibitors are cytostatic but not cytotoxic against cancer cells. To effectively
kill cancer cells without damaging normal tissues, MMP-mediated cytotoxicity is an
appealing solution considering that MMPs are overexpressed in many types of cancer and
their levels are generally lower in healthy tissues. A general strategy to achieve MMP-
mediated cytotoxicity is the incorporation of an MMP-cleavable linker in a delivery
vehicle. This linker serves as a switch such that the therapeutics remain inactive until
proteolysis by an MMP. The different approaches discussed in this section are illustrated
in Figure VI-1.
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Figure VI-1. Schematics of drug delivery vehicles with MMP-cleavable linkers: a) a
polymer-peptide-drug conjugate releases peptidyl-drug after the MMP cleavage to exert
cytotoxic effect on tumor cells; b) a retroviral gene delivery vector with epidermal
growth factor (EGF) linked though MMP-labile peptide is internalized into a tumor cell
after the MMP cleavage; c) the lethal factor (LF) of an anthrax toxin enters the tumor cell
by binding to protective antigens (PAs) after PAs are cleaved by an MMP; d) Upon MMP
cleavage, Interleukin-2 (IL-2) is released from a local depot consisting of the chimeric
proteins of collagen and IL-2
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Polymer-drug conjugates have shown promise in delivering small molecular
weight chemotherapeutics to solid tumors. These soluble conjugates can increase the
half-life of therapeutics, improve the solubility of attached drugs and increase the
targeting ratio through enhanced permeation and retention (as we have discussed in the
previous chapters). Oligopeptide sequences have been investigated as the potential
linkers between drugs and polymers. GFLG is the most widely published one, a linker
that can be cleaved by ubiquitous lysosomal enzymes such as cathepsin B to liberate the
free drugs. We and others have attempted to exploit MMPs to mediate drug release in
order to enhance targeting to MMP-expressing tumors (Figure VI- 1 a).
We have synthesized two types of conjugates: carboxymethyl-peptide-
doxorubicin and dextran-peptide-methotrexate. Both are sensitive towards MMP-2 and
MIMP-9 and able to release peptide-drugs when incubated with the enzymes6' 7. Mansour
has prepared an albumin-peptide-doxorubicin that can release peptide-doxorubicin when
digested by MM:P-2 8. These conjugates are stable in serum: our conjugates remain
uncleaved for at least 24 hours when tested by in vitro experiments and the dextran-
rieptide-methotrexate conjugates remain >99% uncleaved in the blood circulation in vivo;
the half-life for the albumin-peptide-doxorubicin was reported to be about 16 hours in
vitro.
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Injection of the conjugates via the i.v. or i.p. route resulted in superior anti-tumor
effects in MMP-producing tumor models in mice8' 9. However, it is inconclusive whether
MMP-mediation is the dominant targeting mechanism of the albumin-peptide-
doxorubicin conjugate as Mansour's study did not compare the MMP-sensitive conjugate
with the MMP-insensitive conjugate, nor did the in vivo experiments contrast the results
in a MMP-producing tumor model with a MMP-negative model. When comparing the
MMP-sensitive dextran-peptide-methotrexate conjugate with the MMP-insensitive
conjugate, we found that the later exhibited an anti-tumor effect despite being more toxic
systemically 9 (Chapter IV). This prompted us to perform a biodistribution study to
compare the MMP-sensitive, the MMP-insensitive conjugate and the free drug. We
observed a comparable increase in half-life of the two conjugates compared to the free
drug; but we did not observe any significant difference in the tumor accumulation of
peptidyl-drugs between the two conjugates (Chapter V). We have concluded that the
MMP-sensitive dextran-peptide-methotrexate conjugate targets primarily by passive
targeting and enhanced permeation and retention, with MMP-mediated release playing a
modest role.
The challenge of achieving MMP-mediated release from a polymer-drug
conjugate is that the MMP-sensitive peptide linker can be possibly cleaved by other
enzymes in vivo. Presumably upon endocytosis, the conjugate enters the lysosomal
compartment, where many proteases are present. Although the peptide linker is designed
to be most sensitive to MMPs, it is not exclusively labile to the targeted enzyme and can
be a substrate for lysosomal proteases, usually having broad substrate requirements. We
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have incubated our MMP-sensitive conjugate with a mixture of lysosomal enzymes and
found that peptidyl-drug and free drug can be released (data not shown). This release
mechanism enables the conjugate to have a cytotoxic effect without the involvement of
MMPs. Another difficulty is due to the substrate requirement of P3 to P3' sites for the
recognition by MMP-2 or MMP-9. As a result, peptidyl-drug instead of the original free
drug is liberated from the aforementioned conjugates after enzymatic cleavage. The
attachment of several amino acids significantly reduced the potency of the drug. Mansour
suggested that after the initial cleavage by MMP-2, other proteases removed the
remaining amino acids to liberate the free doxorubicin. But his data also showed that free
d oxorubicin was liberated even when MMP-2 was inhibited. The need of non-targeted
proteases to release the free drug weakens the effect of tumor targeting by MMP-
mediated release.
Nevertheless, there are other approaches of MMP-mediated delivery that yield
higher specificity. Peng first described a retroviral gene delivery system that targeted
epidermal fibroblast growth factor receptor (EGFR) whose infectivity depended on
MMPs1° (Figure VI-lb). The epidermal growth factor (EGF) was displayed on the viral
particle via an MMP-cleavable linker. The viral vectors could bind to EGFR on the cell
surface but could not enter the cell, as the receptor did not support the steps to allow for
the viral entry. In the presence of MMPs, EGF was cleaved from the viral particle and the
viral infectivity was restored. The linker was cleavable by both the extracellular MMP-2
and the transmembrane MT1-MMP, and the authors pointed out that the enzymes bound
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on the cell membrane could play a more significant role through a co-culture experiment.
The vector with the MMP-cleavable linker preferentially infected the MMP-expressing
cells over the non-expressing cells when both types of cells were grown in the same
culture dish. Such selectivity should be caused by the enzymatic cleavage at the cell
surface and the subsequent internalization of the virus.
Another example of MMP-mediated cancer therapy is found in a new toxin
prodrug1 (Figure VI-lc). This strategy involves an engineered two-part anthrax toxin.
The cytotoxicity of the anthrax toxin lethal factor (LF) is dependent on the binding to the
heptamer formed by the protective antigens (PAs) and the subsequent internalization of
the complex. The PAs bind to the host cell surface but do not associate to form a channel
until they are cleaved by the cell surface furin or furin-like proteases. Here, the furin
protease cleavage site was mutated to an MMP-2 and MMP-9 cleavable sequence. The
combination of the mutated PA and LF showed selective cytotoxicity in cells
overexpressing the MMPs. More interestingly, it spared the normal cells co-cultured
with the MMP-expressing tumor cells. This specificity requires that the productive
enzymatic cleavage that enables the internalization of LF to happen at the cell surface.
The membrane-bound MT-MMPs or soluble MMPs that remain bound to the cell surface
(through molecules such as MT1-MMP and adhesion receptors) are very likely involved
in the MMP-mediated activation.
Both aforementioned examples showing MMP-mediated specificity rely on cell
surface events and are linked to the MMP cleavage at the membrane. There are four
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known membrane bound MMPs (MT1-,2-,3- and 4-MMP). Some excreted MMPs are
anchored to the cell surface by cell-bound molecules, including MT1-MMP, tav33
integrin and CD44 2-14. The MMP activity on the cell surface, which may help the
cancer cells to establish an invasive front, is more concentrated than that in the interstitial
fluid and can be exploited to cleave the polymer-peptide-drug conjugate. To further
improve the conjugate's specificity, we propose to target the conjugate to the tumor cell
surface by attaching to the conjugate a non-internalizing ligand that recognizes a specific
receptor on the tumor cell. This type of ligand, such as a monovalent fragment of an anti-
tumor antibody15, helps to concentrate the polymer-drug conjugates to the tumor site, and
also places the conjugates in close proximity to the MMPs at the cell surface, increasing
the probability of the conjugates to be cleaved by MMPs rather than by other interstitial
proteases or intracellular enzymes.
Although the specificity of the more recently discovered MT-MMPs is less
extensively studied, targeting these membrane bound enzymes may have an additional
advantage in designing a polymer-peptide-drug conjugate. The consensus sequence
recognized by MT1-MMP includes the substrate sites of P3-P1' 16, instead of the P3-
P3' requirement by MMP-2 and -9. The smaller number of amino acids adjacent to the
scissile bond means that the liberated drug from the conjugate is more similar to the
original form and the drug potency should be less likely reduced.
Besides mediating targeting for a systemic delivery vehicle, MMP activity can be
employed as a release mechanism for a local delivery system (Figure VI-ld). However,
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there are not as many reports in the later category. The example here uses a natural
substrate for MMP as a depot for local release. Hayashi constructed a chimeric protein
joining Interleukin-2 (IL-2) and type III collagen17. IL-2 is a potent chemokine,
considered useful for cancer immunotherapy, and its function includes stimulating the
proliferation of antitumor effector cells. However, IL-2 has a short half-life and toxic side
effects if administered at a high dosage. It was reasoned that the new chimeric protein can
form fibrils like regular collagen, thus shielding and protecting the linked IL-2. As a
proof of concept, he showed that the chimeric was able to liberate biologically active IL-
2 using a bacterial collagenase. This type of construct has the potential of providing a
local delivery of IL-2 at the tumor site, where MMPs are available to digest the collagen
and release the IL-2.
So far, targeted delivery of therapeutics via MMP mediation has been focused on
cancer treatment. There are many new opportunities for expanding this concept to other
diseases in which MMPs have major roles. MMPs are associated with cardiovascular
diseases. Dysregulation of these enzymes are associated with atherosclerosis and heart
failure. MMP-1 and MMP-13 are up-regulated during the left ventricular myocardial
remodeling in congestive heart failure'8. In atherosclerosis, the inflammation at the site of
atherosclerotic plaque recruits the macrophages expressing MMP-1,-8,-13, enzymes
capable of degrading the collagen fibrils. In addition, MMP-2 and MMP-9 are up-
regulated to degrade gelatin after the fibrils unwind. These MMP activities presumably
cause the rupture of the plaque and the progression the disease19. MMPs are also
implicated in the development of arthritis: in both osteoarthritis and rheumatoid arthritis.
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The overexpression of MMP-1 and MMP-13 are involved in breaking down the cartilage
at the affected joint20. With the hypothesis that MMP activity is correlated with disease
progression, a local depot that has an MMP-activatable switch can deliver therapeutics on
demand.
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Disease imaging with MMP-activatable probes
The poor design of some earlier MMP inhibitor clinical trials was partly due to the
lack of a suitable surrogate marker, making it impossible to gauge enzyme activity in
response to a treatment. Inside the body, MMPs are tightly regulated on both the
transcriptional and translational levels. After the MMPs are expressed, their activities are
kept in check with the endogenous inhibitors such as TIMPs and a2-macroglobulins21 .
The pathological process is characterized by the dysregulation of one or more of these
processes, resulting in a net deviation in MMP activity away from normal. These changes
in enzymatic activity are excellent indicators of the prognosis of cancer and other
diseases. It is now known that MMPs are involved at the early stages of cancer
progressionl; monitoring MMP activity can potentially give early diagnosis. All of these
reasons call for the development of smart probes for the in vivo imaging of MMPs.
A smart probe increases or decreases a detectable signal as a result of a biological
event carried out by the molecule of interest. To detect MMPs, this event is their
proteolysis of the peptide or protein substrates. The proteolytic event is essential to the
biological function of the enzyme, whether it is the breaking down of the ECM or the
activation of a growth factor.
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Table VI-2. Cleavage-site motifs for six MMPs2 2
Cleavage position
Enzyme Common P5 P4 P3 P2 P1 P1' P2' P3'
name
MMP-7 Matrilysin P (1.4) V (1.4) P (1.6) L (1.7) S (1.8) L (8.4) V (1.7) M (1.5)
I (1.3) I (1.4)
R (1.3)
MMP- 1 Collagenase- 1 V(1.8)
I(1.4)
V(1.6)
1 (1.5)
M (1.6)
Y (1.4)
V (1.4) P (2.3) M (1.5)
Y (1.4)
L (1.4)
E (1.4)
E (1.6)
N (1.3)
A (1.3)
S (2.2)
N (1.8)
A (1.8)
1(3.6)
M (2.5)
M (4.9)
1(3.8)
L (3.1)
T (1.7)
I(1.5)
M (1.5)
K (1.5)
R (1.3)
M (1.7)
1 (1.5)
K (1.4)
R (1.3)
Y (1.3)
Q (1.3)
A (2.0)
G (1.8)
S (1.6)
MMP-2 Gelatinase A
MMP-9 Gelatinase B
MMP-3 Stromelysin-1
D (1.4)
L (1.3)
F (1.3)
N (1.3)
I(1.3)
I(1.4) P (1.7)
V(1.3) V (1.6)
I(1.5)
V (1.3) S (1.9)
A(1.3) G(1.4)
A (1.4)
E (1.3)
V (1.4) V (1.3) P (2.5) L (1.6)
V (1.6) Y (1.3)
N (1.3) K (1.6)
1(1.3) V(1.4)
I(1.4)
R (1.4)
P (2.5)
V (1.4)
I(1.4)
F (1.5)
Y (1.5)
L (1.4)
M (1.3)
A (1.3)
L (4.2)
M (2.8)
1(2.6)
Y(1.9)
F (1.8)
S (1.8) L (3.4)
M (2.6)
1(2.6)
Y (2.1)
F (1.3)
S (1.6) M (3.5)
E (1.4) 1(2.9)
L (2.5)
Y (2.4)
F (2.1)
MMP-14 MT1-MMP F (1.5)
L (1.4)
D (1.3)
I(1.3)
V (1.3)
1(1.6)
K (1.4)
V (1.3)
D (1.3)
P (2.0)
V (1.4)
X S (1.8) L (3.5)
A (1.4) 1(2.2)
M (2.2)
Y (1.4)
F (1.4)
S (2.2)
A (2.1)
G (2.1)
S (1.9)
A (1.8)
G (1.6)
M (1.6)
A (1.3)
R (1.5)
Y (1.5)
K (1.4)
M (1.4)
I(1.4)
V (1.4)
R (1.4)
T (1.4)
Y (1.4)
V (1.3)
I(1.3)
M (1.9)
K (1.8)
I(1.7)
R (1.6)
R (1.4)
K (1.3)
Y (1.3)
M (1.4)
A (1.4)
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The first type of MMP-activatable probe uses the phenomenon of fluorescence
resonance energy transfer (FRET) to suppress the signals, which are liberated upon the
cleavage of the peptides recognizable by the specific MMPs. Mclntyre and colleagues
developed a smart probe to detect MMP-72 3, an enzyme found in benign intestinal tumors
and tumors of the colon and the breast. For this probe, fluorescein and
tetramethylrhodamine dyes were attached to a PAMAM (polyamido amino) dendrimer
(Figure VI-2a). The emission spectrum of fluorescein overlaps with the excitation
spectrum of tetramethylrhodamine, thus the fluorescein signal is suppressed and the
tetramethylrhodamine signal serves as an internal reference. Fluorescein is covalently
linked to the polymer via a peptide linker labile to MMP-7. Upon cleavage, the
fluorescein signal increases significantly. The limit of using a UV-excitable probe, as in
the previous example, comes mainly from the interference of the host tissues. To solve
this problem, Weissleder's group has pioneered the use of near-infrared
fluorescent fluorophores (NIRF) for probing MMP activity in vivo (Figure VI-2b). For
example, Cy5 dyes are attached via MMP-2 and -9 cleavable peptides to a linear PEG-
grafted polylysine backbone 24. Cy5 are self-quenching probes and so the proteolysis of
MMP-2 or -9 are required to produce an amplified signal. The group developed this
probe with the intention to provide a surrogate marker for MMP inhibitor treatment. They
demonstrated that the treatment with a MMP inhibitor (prinomastat) resulted in a
reduction in the in vivo signal in the MMP-2 and -9 expressing tumor, thereby providing
a readout about the effectiveness of the inhibitor.
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Figure VI-2. Schematics of MMP-activatable imaging probes: a) Fluorescein dyes are
freed upon MMP cleavage from the dendrimer with bound tetramethylrhodamine
molecules resulting in fluorescein signals; b) NIRF dyes are self-quenched when joined
to a polymer backbone and are liberated upon the MMP proteolysis; c) Cell-permeable
peptide carries the NIRF probe into intracellular space after being released from the
linkage with a peptide containing multiple negative charges
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The first type of probe uses a polymeric carrier to enhance the circulation half-
life. The proteolytic event is required to amplify the signal. To increase the signal to
noise ratio, the second type of probe makes use of the proteolytic event of an MMP to
increase the intracellular accumulation of dyes, which are otherwise cleared rapidly from
the body. This approach, developed by Jiang and co-workers, is illustrated in
Figure VI-2c 25. A cell-permeable peptide is a part of this probe, a sequence to
bring a NIRF probe inside a cell. The cell-permeable peptide is highly positively charged
and its internalization capability is abolished by covalently joining to a highly negatively
charged peptide via a MMP-2 and -9 labile linker. The probe is restored to the cell-
permeable form by proteolytic activity; hence it is selectively internalized by the cells
overexpressing MMPs.
As discussed earlier, MMPs are implicated in a number of major diseases. In
addition to their role in imaging cancer, MMP-activatable probes should be useful for the
diagnosis of other MMP-associated diseases. As MMP inhibitors are being developed to
treat these diseases, an MMP-activatable probe is important for monitoring the
effectiveness of MMP inhibition. The family of MMPs consists of many members. In
selecting the therapeutic target, a relevant question is which MMP to inhibit. It will also
be useful for understanding the development of a disease if we can image the activities of
different members of MMPs with multiple probes, or better yet, with a single probe
containing multiple channels. The major challenge is that the cleavable peptide for one
member of MMP is also a substrate for a different member, albeit at a lower rate. As
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shown in Turk's report, the consensus sequences for some MMPs are digested at a rate on
the same order of'magnitude by other MMPs 22 (Table VI-3).
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MMP-responsive material for tissue engineering
A more recent application making use of the MMP-mediation is found in the field
of tissue engineering. The design of a biomimetic material for tissue regeneration has
been of great interest to many research groups. In the natural environments, cells are
surrounded by the extracellular matrix and the process of morphogenesis involves the
degradation and deposition of the extracellular matrix. The active remodeling of the ECM
during tissue regeneration shares some similarities with the process of tumor expansion.
MMPs, whose members can degrade all major components of the ECM, are key
proteases in breaking down ECM to make room for the growing tissues. The ability to
grow vascularized tissues is at the heart of tissue engineering. We have learnt from
cancer biology that MMPs are implicated in tumor angiogenesis, whose activities release
growth factors such as VEGF and expose cryptic angiogenic epitopes in the collagen'. In
the context of tissue engineering, in vitro experiments have demonstrated the importance
of several MT-MMPs with blood vessel growth and tube formation26 2 8. In addition to
providing the mechanical support, ECM is now considered a reservoir of signals that
direct growth and differentiation of the growing tissue. These signals are released in a
cell-mediated manner, by the proteases anchored on the cell membrane or in the
interstitial space. Since ECM components are the natural substrates for MMPs, their roles
in regulating morphogenic cues are important2 .
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Natural materials derived from the ECM are popular for building tissue
engineering scaffolds. Collagen and fibrin, for example, have found uses in bone2 9,
cartilage30 and skin repair31. They can be degraded by an MMP-mediated process.
However, problems such as immunogenicity and disease transmission have caused
concerns for their clinical use. Synthetic materials such as PLGA circumvent these issues.
However, they are usually degraded by hydrolysis and do not reflect the natural process
of tissue remodeling.
Hubbell's lab has pioneered a new class of synthetic materials that mimic the
MMP-driven degradation of the ECM. They developed a network of PEG crosslinked by
oligopeptides that are substrates for MMPs (Figure VI-3a). An example of this type of
PEG gel, with covalently linked RGD-containing peptides as cell attachment signals and
embedded bone morphogenic protein (BMP), was tested in vivo for bone healing3 2.They
demonstrated in vitro that this new gel was susceptible to MMP-1 and the rate of
degradation increased with enzyme concentration. When fibroblasts were seeded on the
gel, invasion fronts were observed as the cells penetrated. Localized instead of bulk
degradation of the gel occurred. This cell-derived degradation process is similar to the
intrinsic ECM remodeling process. This concept has also been applied to an injectable
hydrogel that exhibits phase transition behavior around lower critical solution
temperature (LCST)3 3. Kim and Healy reasoned that when the cartilage was replaced by
the bone during the endochnodral bone formation, type-II collagen was likely degraded
by the MMP-13 secreted by the osteoblasts. They prepared a poly(N-
isopropylacrylamide-co-acrylic acid) hydrogel crosslinked by MMP-13 labile peptides,
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and demonstrated weight loss from the gel as a result of the enzymatic degradation by a
collagenase.
cell
MMP-cleavable peptide
MMP
polymer
MMP-clevable peptide
MMP
VEGF
4;
Figure VI-3. Schematics of MMP-responsive material as tissue engineering scaffolds: a)
polymer chains are crosslinked with MMP-labile sequences and the network is degraded
upon MMP digestion; b) growth factors are covalently bound to the synthetic polymeric
scaffold with MMP-cleavable peptides and the cell-demanded release of the growth
factors is achieved by the proteolytic digestion of MMP
In addition to invading the ECM, the cell-derived MMPs release various growth
factors during the morphogenic process. Vascular endothelial growth factors (VEGF) are
important molecules for inducing angiogenesis as they promote the growth of endothelial
cells. Several isoforms of VEGF bind tightly to the heparin sulfate proteoglycans of the
ECM34. MMP-9 and other MMPs are shown to be able to mobilize the matrix-bound
VEGF35. To imitate this phenomenon, Hubbell's lab covalently linked VEGF to the PEG
hydrogel with an MMP-sensitive linker36 (Figure VI-3b) . They hypothesized that as the
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cells migrate into the PEG gel, the release of VEGF is triggered by the cell-derived MMP
and localized angiogenesis takes place. They demonstrated that, using a CAM assay
(embryonic chick choriallontoic membrane assay), angiogenesis occurred at the gel-
membrane interface. They also showed that vascularized tissue formed within the VEGF-
containing gel when implanted subcutaneously in rats.
Unlike VEGF, which remains biologically active when bound to the ECM,
transforming growth factor-n (TGF- P) is presented as a latent complex bound to the
ECM though its latency-associated peptide (LAP)3 7. A number of MMPs (MMP-2,-9,-13,
and MT1-MMP) are shown to be critical in activating TGF- Pat various stages of
morphogenic development3 8' 39. TGF- P is an important factor with multiple functions,
including the synthesis of ECM4 0. If dysregulated, TGF- P contributes to the pathological
process that comprises of excessive ECM deposition, such as scarring and fibrosis41 . On
the other hand, a controlled ECM synthesis by the seeded cells is necessary in tissue
regeneration. It is attractive to consider mimicking the MMP-mediated activation of
TGF- P in a tissue engineering scaffold. The proteolysis events of MMPs play many roles
in regulating the components of ECM. They also affect how the cells interface with the
surrounding matrix, by cleaving the heparan sulfate proteoglycans on the cell surface
which interact with the ECM molecules4 2. On the other hand, ECM molecules can control
the expression of MMPs via binding to the cell surface heparan sulfate proteoglycans43 .
Further understanding of the biological consequences of these processes, their effects on
cellular differentiation and tissue architecture, should provide useful guidelines to
enhance biomimectic material design employing MMPs as mediators.
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Concluding remarks
Exploiting disease-associated enzymes as mediators is a versatile tool useful in
different biomedical applications. The elegance of this concept is that it relies on a simple
event: the proteolysis of a target enzyme. The widely studied MMPs are interesting
disease-associated enzymes. They are involved in tissue remodeling and many
pathological processes. Their roles have expanded beyond weakening the mechanical
strength of the ECM to releasing important cellular signals and providing biochemical
feedback between the cells and their environments. MMPs have shown tremendous
potentials as mediators in various biomedical applications. We have surveyed the fields
of MMP inhibitor therapy, MMP-triggered drug delivery, MMP-activated imaging and
MMP-responsive biomaterial for tissue engineering. Since the pathological processes
share the common theme of MMP dysregulation, the useful application for one disease -
whether it is MMP inhibitor treatment, imaging or drug delivery - is relevant and
transferable to another disease indication. Significant cross-talking is not only possible
but is synergetic between different biomedical applications. The quest of more specific
substrates for different MMPs is obviously essential for developing MMP inhibitors as
therapeutics, at the same time the results should enable the design of better imaging
probes and drug delivery vehicles mediated by specific MMPs. There are overlaps in the
strategies for making use of MMPs in targeted imaging and targeted drug delivery.
Besides the difference in dose requirement, the major discrepancy is that imaging is
concerned with a snapshot in time and drug delivery considers the cumulative effect over
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time. In addition, MMP-mediated release of signaling molecules on cellular demand is an
appealing approach for tissue engineering. Biomaterials developed for this purpose can
also find applications as local drug delivery depots for the treatment of diseases which are
localized in nature, including but not limited to cardiovascular diseases and arthritis.
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APPENDIX A : Histological illustrations of small intestines from
tumor-bearing mice undergone different treatments
figure A-1. Histological examination of the H&E stained small intestine sections trom
U-87 bearing mice. Tissues were harvested from mice treated with : a) 2 injections of
saline (control); b) 2 injections of free methotrexate ; c) 2 injections of conjugate MTX-
PVGLIG-dextran; d) 1 injection of conjugate MTX-GIVGPL-dextran.
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Figure A-2. Histological examination of the H&E stained small intestine sections from
RT-112 bearing mice. Tissues were harvested from mice treated with : a) 3 injections of
saline (control); b) 3 injections of free methotrexate ; c) 3 injections of conjugate MTX-
PVGLIG-dextran; d) 1 injection of conjugate MTX-GIVGPL-dextran.
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APPENDIX B : Histological illustrations of bone marrows from tumor-
bearing mice undergone different treatments
Figure B-1.Histological examination of the H&E stained bone marrow sections from RT-
112 bearing mice. Tissues were harvested from mice treated with : a) 3 injections of
saline (control); b) 3 injections of free methotrexate ; c) 3 injections of conjugate MTX-
PVGLIG-dextran; d) 1 injection of conjugate MTX-GIVGPL-dextran.
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APPENDIX C : Histological illustrations of livers from tumor-bearing
mice undergone different treatments
Figure C-1. Histological examination of the H&E stained liver sections from RT-112
bearing mice. Tissues were harvested from mice treated with : a) 3 injections of saline
(control); b) 3 injections of free methotrexate ; c) 3 injections of conjugate MTX-
PVGLIG-dextran; d) 1 injection of conjugate MTX-GIVGPL-dextran.
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APPENDIX D : Histological illustrations of kidneys from tumor-
bearing mice undergone different treatments
Figure D-1. Histological examination of the H&E stained kidney sections from HT-1080
bearing mice. Tissues were harvested from mice treated with : a) 3 injections of saline
(control); b) 3 injections of free methotrexate ; c) 3 injections of conjugate MTX-
PVGLIG-dextran; d) 1 injection of conjugate MTX-GIVGPL-dextran.
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Figure D-2. Histological examination of the H&E stained kidney sections from RT-112
bearing mice. Tissues were harvested from mice treated with : a) 3 injections of saline
(control); b) 3 injections of free methotrexate ; c) 3 injections of conjugate MTX-
PVGLIG-dextran; d) 1 injection of conjugate MTX-GIVGPL-dextran.
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APPENDIX E : Histological illustrations of spleens from tumor-bearing
mice undergone different treatments
I
I
Figure E-1. Histological examination of the H&E stained spleen sections from HT-1080
bearing mice. Tissues were harvested from mice treated with : a) 3 injections of saline
(control); b) 3 injections of free methotrexate ; c) 3 injections of conjugate MTX-
PVGLIG-dextran; d) 1 injection of conjugate MTX-GIVGPL-dextran.
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Figure E-2. Histological examination of the H&E stained spleen sections from RT-112
bearing mice. Tissues were harvested from mice treated with : a) 3 injections of saline
(control); b) 3 injections of free methotrexate ; c) 3 injections of conjugate MTX-
PVGLIG-dextran; d) 1 injection of conjugate MTX-GIVGPL-dextran.
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APPENDIX F : Histological illustrations of skin from tumor-bearing
mice undergone different treatments
'..1 "~y - Ib
Figure F-1. Histological examination of the H&E stained skin sections from HT-1080 bearing mice.
Tissues were harvested from mice treated with : a) 3 injections of saline (control); b)
3 injections of free methotrexate ; c) 3 injections of conjugate MTX-PVGLIG-
dextran; d) 1 injection of conjugate MTX-GIVGPL-dextran.
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Figure F-2. Histological examination of the H&E stained skin sections from RT-112
bearing mice. Tissues were harvested from mice treated with : a) 3 injections of saline
(control); b) 3 injections of free methotrexate ; c) 3 injections of conjugate MTX-
PVGLIG-dextran; d) 1 injection of conjugate MTX-GIVGPL-dextran
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